Systems, methods, and kits for diagnosis or treatment planning using extracellular vesicles
The isolation of neuron-derived extracellular vesicles using specific markers and molecular weight cut-off columns addresses the limitations of current blood-based biomarkers, providing a reliable and non-invasive means for diagnosing and monitoring Alzheimer's disease.
Patent Information
- Application Number
- PCT/US2026/027509
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-24
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Current blood-based biomarkers for Alzheimer's disease and related dementias lack region-specificity and do not reflect the same magnitude of change as cerebrospinal fluid, limiting their ability to stage the disease or monitor its progression, and there is a need for cost-effective, easily obtainable biomarkers that can be serially collected without complex instrumentation.
Methods and kits for enriching neuron-derived small extracellular vesicles (NDEs) using specific markers such as SNAP-25, GPM6A, BTBD17, and GABRA1, combined with molecular weight cut-off columns and capture reagents, to isolate pure and consistent NDEs from a heterogeneous population of sEVs.
The method achieves highly pure and reproducible isolation of NDEs, enabling reliable detection of biomarkers for Alzheimer's disease and related dementias, allowing for early diagnosis and monitoring without invasive procedures.
Smart Images

Figure 00000069_0000 
Figure 00000070_0000 
Figure 00000071_0000
Abstract
Description
Atty. Dkt. No. 186563.00009SYSTEMS, METHODS, AND KTTS FOR DIAGNOSIS OR TREATMENT PLANNING USING EXTRACELLULAR VESICLESCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Provisional Patent Application No.63 / 803,192, that was filed May 9, 2025, and U.S. Provisional Patent Application No. 63 / 850,422, that was filed July 24, 2025, the entire contents of each of which are hereby incorporated by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under R21 AG075611 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND
[0003] Blood-based biomarkers are receiving attention as a less invasive approach for the diagnosis and prognosis of Alzheimer's disease (AD) and related dementias (ADRD). However, blood-based biomarkers fail to determine region-specific changes in the AD brain, and do not reflect similar magnitude of change as in CSF, limiting their ability to stage the disease or monitor its progression. Thus, there is an unmet clinical need to discover cost-effective biomarkers that are more easily obtained, can be serially collected, and do not require complex instrumentation.SUMMARY
[0004] In an aspect of the current disclosure, methods of enriching neuron-derived small extracellular vesicles (NDEs) from a plurality of small extracellular vesicles (sEVs) are provided. Small extracellular vesicles (sEVs) include vesicles smaller than 200 nm in diameter, including but not limited to exosomes as defined by current MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. In some embodiments, the methods comprise contacting the plurality of small extracellular vesicles (sEVs) with a binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate a binding reagent-NDE complex, wherein the NDE-specific marker is selected from synaptosome associated protein 25 (SNAP-25), glycoproteinAtty. Dkt. No. 186563.00009M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GABRA1), or a combination thereof.
[0005] In an aspect of the current disclosure, methods are provided. In some embodiments, the methods comprise: centrifuging a sample comprising small extracellular vesicles (sEVs); fdtering the centrifuged sample; treating the filtered sample with at least one of DNase, RNase, or proteinase; separating the treated sample using a molecular weight cut-off column, wherein the plurality of sEVs are isolated in the retentate of the molecular weight column to isolate a plurality of small extracellular vesicles (sEVs); contacting the plurality of sEVs with a binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate a binding reagent-NDE complex, wherein the NDE-specific marker is selected from synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GAB RAI), or a combination thereof; and contacting the binding reagent-NDE complex with a capture reagent to generate a capture reagent-binding reagent-NDE complex, wherein the capture reagent binds to the binding reagent.
[0006] In an aspect of the current disclosure, kits and systems are provided. In some embodiments, the kits or systems comprise at least one binding reagent, wherein the at least one binding reagent is specific for one of synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), or gamma-aminobutyric acid type A receptor subunit alphal (GABRA1) and a capture reagent specific for the binding reagent.BRIEF DESCRIPTION OF THE FIGURES
[0007] FIG. 1 shows “On-Target Brain sEV Capture”, a simple and efficient product to enable highly pure brain-specific small extracellular vesicles (sEV) isolation from plasma to dependably assess ADRD biomarkers.
[0008] FIG. 2 shows Experimental design to discover surface proteome of brain tissue-derived sEV.
[0009] FIGs. 3 A, 3B, and 3C show total sEV analyzed for FIG. 3A. concentration (left panel) and size (right panel) by nanoparticle tracking analysis (NTA), FIG. 3B. Purity and FIG. 3C. expression of various surface markers analyzed by nano-flow cytometry.Atty. Dkt. No. 186563.00009
[0010] FIGs. 4 A, 4B, and 4C show sEV isolated by various methods were labeled with membrane labeling dye and acquired on nano-flow cytometry. FIG. 4B-4C. Isolated sEV were analyzed for size and concentration by NTA.
[0011] FIGs. 5A, 5B, and 5C show FIG. 5A. Isolation efficiency neuron-derived sEV (NDE) from plasma total sEV (n=48) using SNAP-25 marker was compared with LI CAM. NDE were isolated using both markers by conventional method. FIG. 5B. Comparison of conventional NDE isolation method with “On Target” method. NDE size and concentration was analyzed by NTA in FIG. 5A and FIG. 5B. *p<0.05, **p<0.005, ****p<0.0001. FIG. 5C Efficiency of SNAP+ NDE isolation was measured by NTA (left panel) and purity using fluorescent antibodies against SNAP-25 and a neuron specific validation marker synaptophysin (right flow panel).
[0012] FIGs. 6A, 6B, 6C, and 6D show analysis of miR-342-3p in brain regions (frontal cortex, middle temporal gyrus (MTG), and cerebellum) (FIG. 6A), their sEV (middle panel) (FIG. 6B) and NDE isolated from the plasma (FIG. 6C). (FIG. 6D) Bland-Altman plot showed the high concordance between brain tissue and brain tissue-derived sEV for miR-342- 3p expression. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
[0013] FIG. 7 shows NDE were isolated from the plasma of control, MCI and AD individuals and analyzed on NULISAseq platform. Heat map comparing control, MCI and AD NDE for proteins related to neuroinflammation and neurodegeneration biomarkers is shown.
[0014] FIG. 8 shows a schematic presentation of the disclosed total sEV isolation method.
[0015] FIG. 9 shows an overview of isolation of total sEV from plasma / serum and the check points with corrective measures at the major steps.
[0016] FIGs. 10A and 10B show a schematic representation of isolation of cell specific sEV from total sEV. The schematic representation continues from left to right from FIG. 10A, which shows the method through “in cup washing” and FIG. 10B which continues the method after the “in cup washing” step in FIG. 10A.Atty. Dkt. No. 186563.00009
[0017] FIG. 11 shows Immunogold-labeling, coupled with scanning electron microscopy, images of the neuronal sEV isolated using four identified neuron specific markers. Yellow arrows show the gold particles tagged with specific antibodies and represent the presence of neuronal markers.
[0018] FIGs. 12A, 12B, 12C and 12D show neuronal sEV were isolated from plasma of control and MCI individuals using identified four neuron specific marker / s and analyzed for: FIG. 12A. protein cargos, using ultra-sensitive NULISAseq platform for 122 CNS disease associated markers. FIG. 12B. miRNAs cargos using NanoString technology. FIG. 12C. and total RNAs using RNA-seq. NULISAseq data is represented as volcano plots, comparing the significantly altered neuronal sEV proteins between control and MCI individuals. miRNAs expression data is represented as dot plots showing distribution of over 700 miRNAs of neuronal sEV from MCI individuals using control individuals as reference. FIG. 12C Further, RNA-seq data from neuronal sEV is represented as volcano dots (cutoff fold change=2, p= 0.03) comparing sEV from MCI and controls. Few significantly altered RNAs were shown in figure (FIG. 12C). FIG. 12D: Significantly downregulated RNAs were used to analyze molecular function.
[0019] FIG. 13 shows nano-flow cytometry analysis confirm the enrichment of neuronal markers on the surface of isolated NDE. NDE were labeled with membrane labeling dyes along with fluorescently labeled antibodies against neuronal markers. Increased signals on the x-axis confirmed the presence of neuronal markers.
[0020] FIG. 14 shows a schematic representation of the Experimental design to identify the specific markers on sEV surface from three different brain regions. Postmortem brain tissues (frontal Cortex, middle temporal gyrus, and cerebellum) from both cognitively normal and AD individuals (n=12 each, total brain regions n=72), were diced and then digested using collagenase III in Hibernate-E media, and supernatant containing sEV, was sequentially centrifuged to remove the cell debris and larger sized vesicles. Finally, the media was passed through 0.22-micron filter and sEV were isolated using 30% sucrose cushion. Next, sEV were subjected to mild trypsin digestion to extract surface proteins and analysis using mass spectrometry. The initial deconvolution analysis of mass spectrometry data identified SNAP-25, GPM6A, BTBD17, and GABRA1 as surface markers present on sEV from all brain regions, specific to neuronal cell types, and their expression was not affected by the disease status (healthy or AD).Atty. Dkt. No. 186563.00009
[0021] FIGs. 15 A, 15B, 15C, and 15D show brain Tissue (three regions) from healthy and AD (n=12 each) were processed to isolate sEV. FIG. 15A. Representative images of immunogold labeling imaged at 98,000* magnification using TEM, exhibiting the size and surface expression of CD63 and CD81 (black dots on sEV) on cerebellum (CBM), middle temporal gyrus (MTG), and frontal cortex (FC) sEV (scale bar: 100 nm). FIG. 15C and 15D. Dot plots representing the mean size (nm) and concentration (particles / mL) of sEV isolated from brain tissues.
[0022] FIGs. 16A and 16B show Venn diagrams representing the unique and conserved proteins found on the surface of sEV isolated from cerebellum, frontal cortex, and middle temporal gyrus (FIG. 16A) and Alzheimer’s disease enriched sEV surface proteins found in each region (FIG.16B).
[0023] FIGs. 17A and 17B show Venn diagrams representing overlap in proteins identified on sEV from the cerebellum, middle temporal gyrus, and frontal cortex with known EV proteins in Vesiclepedia (FIG. 17A) and ExoCarta (FIG. 17B). Venn Diagrams were prepared with the interact! veVenn software.
[0024] FIGs. 18A, 18B, 18C, 18D, and 18E show NDE were isolated from the plasma of healthy individuals. The biophysical properties of isolated NDE using novel 4 markers were characterized for (FIG. 18A) NDE size and concentration (NTA), (FIG. 18B) protein concentration, estimated using BCA method size, and (FIG. 18C) shape using transmission electron microscopy [TEM]). (FIG. 18D) Surface expression of specific neuronal markers used for NDE isolation, along with typical exosomal tetraspanin markers, were analyzed using super-resolution microscopy. (FIG.18E) Gold-tagged secondary antibodies further confirm the presence of these markers on NDE surface (immunogold labeling [IG] and TEM).
[0025] FIG. 19 (upper and lower panels) shows the purity and neuronal specificity of isolated NDE were characterized using nano-flow cytometry for the levels of neuronal markers, used for NDE isolation (upper panel), and further validated by other commonly used neuron specific markers; L1CAM, ATP1A3, NCAM, SYP (lower panel).
[0026] FIGs. 20A, 20B, 20C, and 20D show The RNA cargo of NDE for neuronal specificity and signals was analyzed using total RNA sequencing (RNA-Seq). NDE were isolated from the plasmaAtty. Dkt. No. 186563.00009of healthy control and MCI individuals (n=6 each) global RNA analysis using RNA-seq was performed. (FIG. 20A) The data, analyzed by BrainDeconvShiny online platform which used CIBERSORT and dtangle comparison matrix, showed that NDE cargos were predominantly enriched for neuronal signature. (FIG. 20B) Further analysis of RNA-seq data revealed a higher number of downregulated mRNA in NDE from MCI individuals. (FIG. 20C) Volcano plot show the statistically significantly altered RNA between healthy control and MCI groups. (FIG. 20D) analysis of the molecular function associated with downregulated genes in MCI identified pathways associated with ncRNA mediated transcriptional regulation and aberration in transcriptional processes.
[0027] FIGs. 21 A and 21B show the isolated total RNA from NDE of healthy control and MCI individuals were further analysis of miRNAs expression using nCounter NanoString platform. FIG.21 A. The overall miRNAs expression is reduced in MCI individuals. FIG. 2 IB. Significantly upregulated (highlighted in red) and downregulated (highlighted in blue) miRNAs (2-fold change) with p value=0.05 are highlighted (right panel).
[0028] FIGs. 22A and 22B show the application of novel markers for isolation NDE in a clinical cohort. Nano particle tracking analysis of NDE, at pre and post dietary interventions, for their size (FIG. 22A) and concentration (FIG. 22B). Importantly, NDE from all participants showed consistent size distribution and yield, irrespective of different interventions.DETAILED DESCRIPTION
[0029] Disclosed herein are methods for enriching neuron-derived small extracellular vesicles (NDEs) from a plurality of small extracellular vesicles (sEVs) and kits and systems for the same.Methods for enriching neuro-derived small extracellular vesicles from a plurality of small extracellular vesicles
[0030] The inventors used an innovative process to discover several markers specific for neuron-derived sEVs (NDEs) (Example 1, FIGs. 18 and 19). The inventors leveraged this discovery to develop methods to enrich for NDEs from a heterogenous population of sEVs, e g., those present in whole blood or plasma.Atty. Dkt. No. 186563.00009
[0031] Accordingly, in an aspect of the current disclosure, methods for enriching NDEs from a plurality of sEVs are provided. In some embodiments, the methods comprise contacting the plurality of small extracellular vesicles (sEVs) with at least one binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate binding reagent-NDE complexes, wherein the NDE-specific marker is selected from synaptosome associated protein 25 (SNAP -25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GAB RAI), or any combination thereof. For example, the at least one binding reagents may comprise 1, 2, 3, or all 4 of SNAP-25, GPM6A, BTBD17, and GAB RAI, in any combination, and may include additional binding reagents.
[0032] In exemplary embodiments, the at least one binding reagent is specific for SNAP -25.
[0033] A “binding reagent” may be, e.g., an antibody, e.g., a monoclonal antibody specific for one of the NDE-specific markers, e.g., an antibody specific for one of SNAP-25, GPM6A, BTBD17, or GABRA1. A binding reagent may be an antigen-binding fragment, e.g., Fab, single chain variable fragment (scFv), etc., of an antibody. This could also be an aptamer, or any affinity moiety capable of selectively recognizing each of these surface markers.
[0034] A “capture reagent,” as used herein, refers to a reagent that binds to the binding reagent to allow capture of the binding reagent-NDE marker complex. For example, the binding reagent may be a biotinylated antibody and the capture reagent may comprise streptavidin. Additional binding-capture pairs are known in the art including, but not limited to, glutathione-glutathione S-transferase, maltose-maltose binding protein, chitin-chitin binding protein, and FITC and FITC-specific antibodies. The biotin may be a photocleavable biotin tag. A variety of binding reagents, e.g., anti-biotin antibodies, are known in the art.
[0035] The capture reagent may be linked to a solid substrate, e.g., bead, column, lateral flow assay, etc. The solid substrate may allow for in assay washing, purification, elution, etc. The capture reagent and binding reagent may be released from the NDEs to allow elution of free NDEs.
[0036] Molecular weight cut-off columns / assays are used herein to further enrich sEVs from all extracellular vesicles (EVs). In some embodiments, 300 kDa molecular weight cut-off columns are used. The sEVs are found in the retentate of molecular weight cut-off columns. See also KumarAtty. Dkt. No. 186563.00009etal. “Small extracellular vesicles in plasma reveal molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment.” Brain Communications, 4(6), doi.org / 10.1093 / braincomms / fcac262, which is incorporated by reference herein.
[0037] The inventors leveraged the disclosed methods to interrogate the transcripts present in NDEs from subjects suffering from mild cognitive impairment (MCI) and subjects suffering from Alzheimer’s disease (AD) (FIG. 20). Accordingly, the methods may further comprise detecting at least one marker in the enriched NDEs, e.g, MiR-342-3p, phosphoglycerate kinase 1 (PGK1), GDP dissociation inhibitor 1 (GDI1), interleukin 15 (IL-15), placental growth factor (PGF), PDZ And LIM Domain 5 (PDLIM5), SLP adaptor and CSK interacting membrane protein (SCIMP), citron Rho-interacting serine / threonine kinase (CIT), collagen type VI alpha 2 chain (COL6A2), Histonelysine N-methyltransferase 2A (KMT2A), N0TCH3, Family With Sequence Similarity 78 Member A (FAM78A), Stromal Antigen 2 (STAG2), Multiple Epidermal Growth Factor-like Domains 8 (MEGF8), Scaffold Attachment Factor B (SAFB), Ubiquitin Specific Peptidase 34 (USP34), Adhesion G Protein-Coupled Receptor G1 (ADGRG1), Lemur Tyrosine Kinase-2 (LMTK2), RNA Exonuclease 1 Homolog (REX01), DENN Domain Containing 4B (DENND4B), Polyadenylate-binding protein 2 (PABPN1), Mitogen-Activated Protein Kinase 1 (MAPK1), Zinc Finger CCHC-Type Containing 7 (ZCCHC7), tao kinase 1 (TA0K1), triosephosphate isomerase 1 (TPI1), Myeloid / Lymphoid Or Mixed-Lineage Leukemia, Translocated To, 6 (MLLT6), or a combination thereof.
[0038] Detecting at least one marker may be accomplished using methods known in the art, e.g., nucleotide sequences, proteomics, e.g., mass spectroscopy, NMR, or immunological assays, e.g., immunofluorescence, enzyme-linked immunosorbent assays (ELISA), e.g., nucleic acid linked immuno-sandwich assay (see, e.g., Feng et al. “NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing” Nature Communications volume 14, Article number: 7238 (2023), which is incorporated by reference herein.
[0039] The present invention is described herein using several definitions, as set forth below and throughout the application.Kits and SystemsAtty. Dkt. No. 186563.00009
[0040] Kits and systems are also disclosed herein. The kits and systems may comprise at least one binding reagent, wherein the at least one binding reagent is specific for one of synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), or gamma-aminobutyric acid type A receptor subunit alphal (GAB RAI) and a capture reagent specific for the binding reagent.
[0041] The kits and systems may further comprise at least one of (a) a cell filter; (b) DNase; (c) RNase; (d) proteinase; (e) a molecular weight cut-off column; (f) specific antibody or antibodies with or without already conjugated to streptavidin coated beads (agarose or magnetic); or (g) streptavidin coated beads- agarose or magnetic. An antibody -biotin system could be replaced with specific aptamers-biotin system specific for one of synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), or gamma-aminobutyric acid type A receptor subunit alphal (GABRA1) and a capture reagent specific for the binding reagent.Definitions
[0042] The disclosed subject matter may be further described using definitions and terminology as follows. The definitions and terminology used herein are for the purpose of describing particular embodiments only and are not intended to be limiting.
[0043] As used in this specification and the claims, the singular forms “a,” “an,” and “the” include plural forms unless the context clearly dictates otherwise. For example, the term “a substituent” should be interpreted to mean “one or more substituents,” unless the context clearly dictates otherwise.
[0044] As used herein, “about”, “approximately,” “substantially,” and “significantly” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” and “approximately” will mean up to plus or minus 10% of the particular term and “substantially” and “significantly” will mean more than plus or minus 10% of the particular term.Atty. Dkt. No. 186563.00009
[0045] As used herein, the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising.” The terms “comprise” and “comprising” should be interpreted as being “open” transitional terms that permit the inclusion of additional components further to those components recited in the claims. The terms “consist” and “consisting of’ should be interpreted as being “closed” transitional terms that do not permit the inclusion of additional components other than the components recited in the claims. The term “consisting essentially of’ should be interpreted to be partially closed and allowing the inclusion only of additional components that do not fundamentally alter the nature of the claimed subject matter.
[0046] The phrase “such as” should be interpreted as “for example, including.” Moreover, the use of any and all exemplary language, including but not limited to “such as”, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
[0047] Furthermore, in those instances where a convention analogous to “at least one of A, B and C, etc.” is used, in general such a construction is intended in the sense of one having ordinary skill in the art would understand the convention (e.g., “a system having at least one of A, B and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description or figures, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or ‘B or “A and B.”
[0048] All language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can subsequently be broken down into ranges and subranges. A range includes each individual member. Thus, for example, a group having 1-3 members refers to groups having 1, 2, or 3 members. Similarly, a group having 6 members refers to groups having 1, 2, 3, 4, or 6 members, and so forth.
[0049] The modal verb “may” refers to the preferred use or selection of one or more options or choices among the several described embodiments or features contained within the same. Where no options or choices are disclosed regarding a particular embodiment or feature contained in theAtty. Dkt. No. 186563.00009same, the modal verb “may” refers to an affirmative act regarding how to make or use and aspect of a described embodiment or feature contained in the same, or a definitive decision to use a specific skill regarding a described embodiment or feature contained in the same. In this latter context, the modal verb “may” has the same meaning and connotation as the auxiliary verb “can.”
[0050] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.Illustrative Embodiments1. A method of enriching neuron-derived small extracellular vesicles (NDEs) from a plurality of small extracellular vesicles (sEVs), the method comprising contacting the plurality of small extracellular vesicles (sEVs) with a binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate a binding reagent-NDE complex, wherein the NDE-specific marker is selected from synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GABRA1), or a combination thereof.2. The method of embodiment 1, wherein the method further comprises contacting the binding reagent-NDE complex with a capture reagent to generate a capture reagent-binding reagent-NDE complex, wherein the capture reagent binds to the binding reagent.3. The method of embodiment 2, wherein the method further comprises washing the capture reagent-binding reagent-NDE complex and / or eluting the enriched NDEs from the capture reagent-binding reagent-NDE complex.4. The method of any one of the preceding embodiments, wherein the plurality of sEVs are isolated from a sample from a subject by centrifuging the sample, filtering the centrifuged sample, treating the filtered sample with at least one of DNase, RNase, or proteinase, and separating the treated sample using a molecular weight cut-off column, wherein the plurality of sEVs are isolated in the retentate of the molecular weight cut-off column.Atty. Dkt. No. 186563.000095. The method of embodiment 4, wherein centrifuging comprises centrifuging the sample at about 2000xg for about 1 to about 20 min.6. The method of embodiment 4 or 5, wherein fdtering the centrifuged sample comprises fdtering the centrifuged sample through a 0.22 pm fdter.7. The method of any one of embodiments 4-6, wherein the molecular weight cut-off column has a cut-off of greater than about 100 kDa, greater than about 150 kDa, greater than about 200 kDa, greater than about 250 kDa, greater than about 300 kDa, greater than about 350 kDa, greater than about 400 kDa, greater than about 500 kDa, optionally, wherein the cut-off is about 300 kDa.8. A method comprising:centrifuging a sample comprising small extracellular vesicles (sEVs);fdtering the centrifuged sample;treating the fdtered sample with at least one of DNase, RNase, or proteinase; separating the treated sample using a molecular weight cut-off column, wherein the plurality of sEVs are isolated in the retentate of the molecular weight column to isolate a plurality of small extracellular vesicles (sEVs);contacting the plurality of sEVs with a binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate a binding reagent-NDE complex, wherein the NDE-specific marker is selected from synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GAB RAI), or a combination thereof; andcontacting the binding reagent-NDE complex with a capture reagent to generate a capture reagent-binding reagent-NDE complex, wherein the capture reagent binds to the binding reagent.9. The method of embodiment 4, wherein centrifuging comprises centrifuging the sample at about 2000xg for about 1 to about 20 min.10. The method of embodiment 8 or 9, wherein fdtering the centrifuged sample comprises fdtering the centrifuged sample through a 0.22 pm fdter.Atty. Dkt. No. 186563.0000911. The method of any one of embodiments 8-10, wherein the molecular weight cutoff column has a cut-off of greater than about 100 kDa, greater than about 150 kDa, greater than about 200 kDa, greater than about 250 kDa, greater than about 300 kDa, greater than about 350 kDa, greater than about 400 kDa, greater than about 500 kDa, optionally, wherein the cut-off is about 300 kDa.12. The method of any one of embodiments 8-11, wherein the method further comprises washing the capture reagent-binding reagent-NDE complex and / or eluting the enriched NDEs from the capture reagent-binding reagent-NDE complex.13. The method of any one of the preceding embodiments, wherein the NDE-specific marker is SNAP-25.14. The method of any one of the preceding embodiments, wherein the binding reagent is an antibody or an antigen-binding fragment thereof.15. The method of embodiment 14, wherein the antibody is a monoclonal antibody.16. The method of any one of the preceding embodiments, wherein the capture reagent is linked to a solid substrate.17. The method of embodiment 16, wherein the solid substrate comprises beads, optionally, wherein the beads are agarose beads or magnetic beads.18. The method of any one of the preceding embodiments, wherein(i) the binding reagent comprises biotin and the capture reagent comprises streptavidin; (ii) the binding reagent comprises glutathione and the capture reagent comprises glutathione S-transferase;(iii) the binding reagent comprises maltose and the capture reagent comprises maltose binding protein;(iv) the binding reagent comprises chitin and the capture reagent comprises chitin binding protein; or(v) the binding reagent comprises fluorescein isothiocyanate (FITC) and the capture reagent comprises a FITC-specific antibody.Atty. Dkt. No. 186563.0000919. The method of embodiment 18, wherein the binding reagent comprises biotin and the capture reagent comprises streptavidin.20. The method of any one of embodiments 4-19, wherein the sample comprises blood or plasma.21. The method of any one of the preceding embodiments, wherein the method further comprises detecting at least one marker in the NDEs.22. The method of embodiment 21, wherein detecting comprises enzyme linked immunosorbent assay (ELISA).23. The method of embodiment 22, wherein the ELISA comprises a nucleic acid linked immuno-sandwich assay.24. The method of any one of embodiments 21-23, wherein the at least one marker comprises MiR-342-3p, phosphoglycerate kinase 1 (PGK1), GDP dissociation inhibitor 1 (GDI1), interleukin 15 (IL-15), placental growth factor (PGF), PDZ And LIM Domain 5 (PDLIM5), SLP adaptor and CSK interacting membrane protein (SCIMP), citron Rho-interacting serine / threonine kinase (CIT), collagen type VI alpha 2 chain (COL6A2), Histone-lysine N-methyltransferase 2 A (KMT2A), NOTCH3, Family With Sequence Similarity 78 Member A (FAM78A), Stromal Antigen 2 (STAG2), Multiple Epidermal Growth Factor-like Domains 8 (MEGF8), Scaffold Attachment Factor B (SAFB), Ubiquitin Specific Peptidase 34 (USP34), Adhesion G Protein-Coupled Receptor G1 (ADGRG1), Lemur Tyrosine Kinase-2 (LMTK2), RNA Exonuclease 1 Homolog (REX01), DENN Domain Containing 4B (DENND4B), Polyadenylate-binding protein 2 (PABPN1), Mitogen-Activated Protein Kinase 1 (MAPK1), Zinc Finger CCHC-Type Containing 7 (ZCCHC7), tao kinase 1 (TAOK1), triosephosphate isomerase 1 (TPI1), Myeloid / Lymphoid Or Mixed-Lineage Leukemia, Translocated To, 6 (MLLT6), or a combination thereof.25. A kit or system comprising at least one binding reagent, wherein the at least one binding reagent is specific for one of synaptosome associated protein 25 (SNAP-25), glycoproteinAtty. Dkt. No. 186563.00009M6A (GPM6A), BTB domain containing 17 protein (BTBD17), or gamma-aminobutyric acid type A receptor subunit alphal (GABRA1) and a capture reagent specific for the binding reagent.26. The kit or system of embodiment 25, wherein the kit comprises at least two binding reagents.27. The kit or system of embodiment 25 or 26, wherein(i) the binding reagent comprises biotin and the capture reagent comprises streptavidin; (ii) the binding reagent comprises glutathione and the capture reagent comprises glutathione S-transferase;(iii) the binding reagent comprises maltose and the capture reagent comprises maltose binding protein;(iv) the binding reagent comprises chitin and the capture reagent comprises chitin binding protein; or(v) the binding reagent comprises fluorescein isothiocyanate (FITC) and the capture reagent comprises a FITC-specific antibody.28. The kit or system of any one of embodiments 25-27, wherein the kit or system further comprises at least one of:(a) a cell filter;(b) DNase;(c) RNase;(d) proteinase; or(e) a molecular weight cut-off column.29. The kit or system of any one of embodiments 25-28, wherein the kit or system further comprises instructions for performing the methods of any one of embodiments 1-24 using the kit or system.30. The kit of any one of embodiments 25-28, wherein the kit consists of a defined ready to use mixture of antibody-biotin-streptavidin-beads, optionally, wherein the beads are agarose or magnetic beads.Atty. Dkt. No. 186563.00009EXAMPLES
[0051] The following Examples are illustrative and should not be interpreted to limit the scope of the claimed subject matter.Example 1 - Isolation and analysis of neuron-derived small extracellular vesicles (NDEs)
[0052] Brain specific NDEs will be isolated from plasma or serum using our method which will be compatible with multiple downstream assays such a protein, RNA, DNA, lipid, and metabolite analyses. However, our approach is not limited to isolating NDEs from serum or plasma but from any biofluid as our surface markers are specific to NDEs secreted by neurons in the central nervous system. So, this approach will be applicable to NDEs isolation from urine, CSF, saliva or any other bodily fluids.
[0053] Existing methods for isolating total small extracellular vesicles (sEVs) are plagued by inconsistency and impurities. Current approaches yield unreliable results and impure sEVs, lacking the precision needed for advanced research. Additionally, there are no reliable surface markers to specifically isolate brain-derived sEVs, which has stymied progress and dampened enthusiasm in the field.
[0054] Our innovative approach changes this paradigm. Leveraging our unique expertise and cutting-edge discoveries of novel surface markers, we are uniquely positioned to lead this effort. Our groundbreaking kit, ‘on-Target Brain sEV Capture’, addresses these challenges head-on, offering consistent, pure sEV isolation and reliable brain cells-specific markers. This breakthrough will reignite excitement among researchers and propel advancements in understanding neurological disorders.
[0055] To overcome the limitations of existing methods and improve consistency, we implemented several innovative strategies:
[0056] Novel principle for isolation: We adopted ‘exclusion’ based approach by prioritizing removal of larger vesicles, and all non-EV components from plasma and serum, ensuring the collection of pure, total sEVs.Atty. Dkt. No. 186563.00009
[0057] Unique Washing Steps: Our washing steps, which include special cups with filters, enhance removal of non-EVs contaminants without losing the target population of sEVs, improving overall purity.
[0058] Focused Purification: We incorporated steps to eliminate larger vesicles, free DNA, RNA, proteins, and smaller non-specific EVs, ensuring a pure and targeted EV population. We optimize a precise concentration of DNAase, RNAase and proteinases for this purpose.
[0059] Targeted capture: We have discovered unique surface markers on sEVs secreted by specific brain cell types, uniquely positioning us to isolate brain cell-specific sEVs from peripheral blood.
[0060] These advancements collectively ensure the consistent, pure isolation of targeted sEVs, addressing the significant challenges faced by current methods.
[0061] Our revolutionary product, ‘on-Target Brain sEV Capture’, is set to transform the field of neurological research. This cutting-edge kit isolates brain neuron-specific small extracellular vesicles, opening new avenues for both basic scientists and clinicians. Imagine the breakthroughs: discovering novel biomarkers and precisely assessing established ones for Alzheimer's disease and several other neurological disorders, without expensive imaging techniques, directly from the blood. This innovative tool promises to propel advancements and unveil the molecular mysteries of the brain like never before
[0062] Specific Aims
[0063] Alzheimer's disease (AD) and related dementias (ADRD) represent complex incurable neurodegenerative disorder, currently affecting ~6.9 million Americans, and caused 119,399 certified deaths from AD in 20211. AD is currently a public health crisis and is considered the most expensive disease to manage in the United States. The current approaches that are based upon cognitive testing, assessment of cerebrospinal fluid (CSF), and neuroimaging measures provide clinical diagnosis only when significant and irreversible neuronal damage has already occurred. Early diagnosis of AD might allow delay its progression in a proportion of the population by modifying exposure to risk factors and more importantly, aware the individuals and their care givers to make choices for treatments / interventions that can help manage symptoms. In this regard,Atty. Dkt. No. 186563.00009blood-based biomarkers have become increasingly attractive for detecting and monitoring AD-related pathological proteins; however, the levels of these proteins may also be contributed by peripheral organs and therefore lack brain specificity.
[0064] In the last decade, small extracellular vesicles (sEVs) have emerged as an excellent tool for diagnosis and prognosis of multiple diseases including neurodegenerative diseases. To a great extent, cargo of sEVs reflect the pathophysiological state of the parent cell; their analysis could provide treasured information about the parent cells in a given condition and therefore considered potential noninvasive blood-based biomarkers. The ability of brain cell-derived sEVs to cross blood-brain barrier into systemic circulation and their relatively easy isolation from biofluids make them an attractive candidate for AD biomarkers’ discovery. The analysis of pathological proteins related to amyloidopathy and tauopathy in neuron-derived sEVs (NDEs) from the biofluids of AD individuals has been shown to predict the development of AD 5-10 years prior to its clinical onset. Beyond protein-based biomarkers, we have identified several miRNAs in brain cells-derived sEVs and extensively reported their usefulness as potential molecular biomarkers for diagnosis of dementia. Overall, brain cell- derived sEVs have emerged as an exciting liquid biopsy tool for ADRD and other neurological disorders .
[0065] Despite the promising findings suggesting the usefulness of brain cell-derived sEVs in neurological disorders, these vesicles are currently not approved for clinical use, majorly due to technical challenges associated with their isolation and characterization. The foremost and persistent challenge in the field is the central nervous system (CNS) specificity of biomarkers used forbrain cell specific sEVs isolation. Furthermore, lack of purity, consistency, and reproducibility of sEVs isolation has dampened enthusiasm in the field. Understanding the potential of sEVs as ‘liquid biopsy’ and the need of consistent, feasible, and reproducible tool to isolate highly pure and specific sEV, we propose “On-Target Brain sEV Capture” as a reliable solution overcoming the current challenges. Based on our extensive expertise in the sEVs field and years of experience in isolating brain cell specific sEVs from blood, and most importantly our unique approaches to discover cell or tissue specific sEV surface markers, we intend to design this product as a simple, efficient, and reproducible framework to isolate highly pure and brain cell specific sEVs from blood for the development of reliable blood-based biomarkers for ADRD. The major aims of developing this product for research and clinical use are:Atty. Dkt. No. 186563.00009
[0066] Optimizing methodology for the Isolation of pure neuron-derived sEV (NDF.) from plasma. The isolation of NDE from blood is a multistep process and is approached as following integrated tasks. 1. Isolation of total sEVs (TE)from plasma will be performed by a simple though efficient ‘exclusion based’ approach, i.e. by removing all non-sEVs components from plasma and concentrating pure sEVs 2. NDEs will be isolated from total sEVs using a cocktail of specific surface markers, SNAP-25, GPM6A, BTBD17, and GABRA1, identified by us from the mass spectrometry analysis of the surface proteome of sEVs isolated from specific human brain regions. The choice of surface markers for NDEs isolation is flexible, and as needed, additional markers will be considered from our brain sEVs surface proteome data. We will continue to identify sEVs surface markers specific for other brain cells. 3. Extensive characterization of isolated NDEs is performed for their size and concentration by nanoparticle tracking analysis (NTA); purity and specificity by nano-flow cytometry, neuron specific protein array, immuno-gold labeling with transmission electron microscopy and super resolution microscopy
[0067] Further characterization of isolated NDEs and their cargo was performed to establish consistency and reproducibility. Protein content of isolated NDE was analyzed on NULISAseq platform (-120 target CNS panel proteins) and panel of 8 miRNAs, to establish the utility of NDE in distinguishing control from AD individuals. We also characterized the gene expression and miRNA expression in the isolated NDEs from the plasma of individuals with normal cognition, mild-cognitive impairment and Alzheimer’s disease. Overall, isolated NDEs are compatible to discover novel AD biomarkers based upon protein, RNA or other biomolecules such as DNA, lipids or metabolites.
[0068] Overall, leveraging our unique expertise and cutting-edge discoveries of novel sEVs surface markers, we are uniquely positioned to lead the development of a groundbreaking product, “on-Target Brain sEV Capture”, which will address the challenges of total as well as brain specific sEVs isolation, offering consistent, pure sEVs isolation and assessment of reliable biomarkers for ADRD.
[0069] Blood-based biomarkers are receiving attention as a less invasive approach for the diagnosis and prognosis of Alzheimer's disease (AD) and related dementias (ADRD). However, blood-based biomarkers fail to determine region-specific changes in the AD brain, and do notAtty. Dkt. No. 186563.00009reflect similar magnitude of change as in cerebrospinal fluid (CSF), limiting their ability to stage the disease or monitor its progression21. Thus, there is an unmet clinical need to discover cost-effective biomarkers that are more easily obtained, can be serially collected, and do not require complex instrumentation. Small extracellular vesicles (sEVs)- based biomarkers could fulfill this need. sEV are lipid membrane-bound vesicles, with size <200 nm in diameter, which carry a wide range of biomolecules as cargo, and can be isolated from diverse biofluids, representing excellent source for ‘liquid biopsies.’ Despite the enormous potential of sEVs as a source of biomarker for ADRD, the complex workflow, inconsistencies, and lack of purity and reproducibility in sEVs isolation, make their clinical utility challenging. Especially, for brain cell- derived sEVs to reach to their potential, advancement on the development and validation of techniques for their isolation and characterization is imperative. Here, we propose the development of “On-Target Brain sEV Capture” as a unique, simple, efficient and consistent solution for these limitations (FIG. 1).
[0070] Brain cells-derived small extracellular vesicles (sEVs): Emerging role as ‘liquid biopsy.’ In last one decade, sEVs have gained much attention as a source of biomarker for multiple diseases, including ADRD2. sEVs content, including nucleic acids, proteins, and metabolites, are protected while in circulation, making them an efficient means for intercellular communication. These vesicles are present in all biofluids and their cargo relate to the cell of origin and their physiological / metabolic state. The ability of brain cell-derived sEVs to cross blood-brain barrier (BBB) into systemic circulation and the technological advancement in sEVs field, which allow their isolation from diverse biofluids, has generated enthusiasm for their potential as noninvasive biomarker2-4’44For example, protein markers in neuron-derived sEVs (NDEs) from the biofluids of AD individuals have been shown to predict the development of AD 5-10 years prior to its clinical onset. We reported that neurodegeneration and neuro-inflammation biomarkers in brain cells-derived sEVs in plasma closely correlated with a decrease in the gray matter volume of specific lobes of the brain in cynomolgus monkeys. Similarly, we reported that miRNAs loaded in different brain cell-derived sEVs have not only excellent biomarker potential but also could reveal the molecular pathways active during AD pathogenesis; strongly positioning brain cell-derived sEV as ‘liquid biopsies’ and a source for AD biomarkers. However, inconsistency in total sEVs and NDEs isolation across different labs, has resulted in variation and discrepancies in findings; thereby, muddling the growth in this field and stifling the potential clinical translation.Atty. Dkt. No. 186563.00009
[0071] Current approaches for the isolation of neuron-derived sEVs (NDEs) from biofluids. The isolation of cell type specific sEVs from biofluids is a multistep process. The first step involves isolating total sEVs from the biological sample, such as blood plasma or serum. This is achieved through methods such as ultracentrifugation, precipitation, density gradient centrifugation, size exclusion chromatography, filtration, immuno-affinity capture, and microfluidic chip. However, isolation of NDE by immune-precipitation is the most widely used method. Several markers have been used to isolate NDE from plasma or serum total sEV, with LI cell adhesion molecule (L1CAM / CD171) being the most commonly used. However, L1CAM specificity to neurons or even the central nervous system has been questioned. Similarly, the choice of markers for other brain cells-derived sEVs isolation is either based on the expression of proteins on the surface of parent cells, or in-silico predictions. None of the existing biomarkers have strong basis of their use to isolate CNS neuron-specific sEVs. Our methodology is based on solid and innovative foundation offering CNS specificity to markers used to isolate NDEs from blood plasma or serum.
[0072] Limitations of the current brain cell-derived sEVs isolation methods. The traditional methods for total sEVs isolation are not only tedious and costly, but also could require specialized instruments. Total sEVs isolation by these methods usually could disrupt their biophysical integrity. In addition, conventional isolation techniques limit scaling-up of sEVs isolation due to intra- and inter-batch variations. Most of the current technologies are time-intensive, require tedious manual labor, and are prone to lipoprotein and other contamination. For clinical translation, especially for therapeutic purposes, sEVs isolation technologies should be scalable, more automated, selective to specific sEV subpopulations, and able to handle complex biological fluids. Additionally, total sEVs isolated using these methods contain high amount of non-EV contaminants and make them unsuitable for brain specific sEV isolation. Most sEV isolation methods precipitate everything (including free proteins and cell free DNA / RNA) present in the plasma. Alternatively, size exclusion chromatography separates vesicles into a narrow size range, excluding large amount of sEVs, and produces diluted samples requiring further concentration. Therefore, there is no existing method that provides efficient, consistent, less complicated, and pure sEVs from blood, which renders high capability of sEVs research in neurological disorders. Further, isolation of brain- specific sEVs using antibody based immune-precipitation method requires specific surface marker / s, but the evidence-based selection of these markers is still not adopted by any commercial product.Atty. Dkt. No. 186563.00009
[0073] Innovation. The proposed study is highly innovative based on the following reasons: The proposed development of “On-Target Brain sEV Capture” as a commercial product to isolate highly pure and specific brain specific sEVs is leveraged from our identified highly specific markers present on brain derived sEVs surface. We have performed our innovative “surface shaving method” on sEV isolated from different brain regions, and mass spectrometry analysis identified SNAP-25, GPM6A, BTBD17, and GABRA1 as specific markers expressed on sEV surface. Using these innovative approaches, we are the first one to identify several novel surface markers for CNS specific NDE and other brain cell-derived sEV, in a region-specific manner.
[0074] Our approach to isolate total sEVs from plasma is based on our simple workflow which overcomes challenges associated with sEVs isolation, ensuring consistent and pure sEVs isolation from plasma. We adopted an ‘exclusion’ based approach by removing all non-sEV components from plasma and concentrating pure sEVs. Also, by modifying steps that introduce variability, we have achieved pure and consistent sEV isolation.
[0075] The isolated NDEs are extensively characterized for purity and specificity by well-established and cutting- edge techniques, such as nano-flow cytometry, NULlSAseq multiplex platform with attomolar (10IKmoles per liter) sensitivity65.
[0076] Approach.
[0077] Here, we have proposed to design a product “On-Target Brain sEV Capture” for the isolation of pure and specific NDEs from plasma. Our workflow overcomes the challenges and limitations of the current sEV isolation methods, minimizing inter-person and batch-to-batch variations and yielding highly pure NDEs for the development of reliable blood-based biomarkers for AD RD
[0078] Preliminary data
[0079] Discovering novel NDE specific surface markers. sEVs were isolated from three different brain regions from healthy and AD individuals (n=12 each) following our published method. The postmortem brain tissues were diced and digested using collagenase III (FIG. 2). The media supernatant, containing sEVs, was sequentially centrifuged to remove any cell debris and passedAtty. Dkt. No. 186563.00009through 0.22pm filter and sEV isolated using 30% sucrose cushion as described by us. sEV were subjected to mild trypsin digestion.
[0080] The digestion to extract surface proteins and analyzed by mass spectrometry (MS) as reported by us. The initial analysis of MS data identified SNAP-25 (synaptosome associated protein 25), GPM6A (glycoprotein M6A), BTBD17 (BTB domain containing 17 protein), and GAB RAI (gamma-aminobutyric acid type A receptor subunit alphal) as surface markers present on sEV from all brain regions, specific to neuronal cell types, and their expression was not affected by the disease status (healthy or AD). Therefore, these markers were initially prioritized to isolate NDEs from plasma without being biased for AD related pathology.
[0081] Consistent isolation of total sEV using “On-Target” workflow. In the feasibility study, we used control plasma sample and distributed that into 250pl aliquots to access the consistency of total sEV and NDE isolation. Four aliquots of plasma samples for each independent experiment were first centrifuged at 2,000xg for 10 min at 4°C followed by filtration through 0.22pm filter, and treatment with DNase and RNase. Samples were then loaded on a 300 KDa molecular weight cutoff column for centrifugation at lOOOxg for 5 min. The collected ‘flow through’ was analyzed for any loss of sEV at this step. Finally, sEV were recovered from the column and extensively characterized. Nanoparticle tracking analysis (NTA) data from three independent experiments showed >85% consistency in concentration and size of isolated total sEV (FIG. 3A). Total sEV were labeled with membrane labeling dye and analyzed on nano-flow cytometry, which confirmed that >85% isolated sEV were dye positive (FIG. 3B-middle panel). The analysis of ‘flow through’ confirmed the absence of the membrane bound particles, hence no loss of sEV during isolation (FIG. 3B-lower panel). Furthermore, typical sEV markers, CD63 and CD81 showed -63% and -50% expression respectively on total sEV; and SNAP -25 was found to be present on -5% total sEV (FIG. 3C).
[0082] ‘ ‘On-Target” method showed superior purity, and total sEV isolation efficiency compared to conventional methods. We further compared the efficiency and purity of total sEV isolation using precipitation (ExoQuick) and ultracentrifugation methods with our novel “On-Target” sEV capture” method. sEV isolated from all three methods were labeled with lipid membrane labeling dye and acquired on nano-flow cytometer (CytoFlex). The results (FIG. 4A) clearly showed thatAtty. Dkt. No. 186563.00009sEV isolated from “On-Target” method showed >85% membrane bound particles compared to -30% from ExoQuick and -60% with ultracentrifugation method. Further, NTA analysis also showed comparable number and size of particles isolated with “On- Target sEV capture” method and precipitation-based method, while ultracentrifugation yielded least sEV concentration (FIG.4B-4C).
[0083] “On-Target” method / markers provided higher NDEs recovery and yield over conventional method / markers. To compare the isolation efficiency, NDEs were isolated using SNAP-25- and LI CAM- biotinylated antibodies, from plasma total sEV (n=48) by conventional immunoprecipitation followed by immune-isolation method and compared for size and concentration. SNAP -25 as isolation marker, provided better yield compared to LI CAM (FIG.5A). Further, we compared the conventional isolation method with “On-target” method using SNAP-25 marker and found higher recovery of NDEs using “On-target” method. “On-Target” method provided higher concentration and smaller sized NDEs compared to conventional method using SNAP-25 marker in both methods (FIG. 5B). Next, NDEs were isolated from total sEV by incubating with biotin-SNAP-25 antibody using “On-Target” method. Total sEV with SNAP-25 antibody and streptavidin coated agarose beads were loaded on to cellulose acetate cups / filters. Washing of the beads to remove non-SNAP-25+ sEV and free unbound antibody was performed on cups, to minimize the loss of beads and SNAP -25+ NDEs. The elution of NDE was performed on these cups to maximize recovery. Concentration of NDEs showed that 3-4% of the total sEV were isolated as SNAP+ NDEs. Based on SNAP-25 presence on total sEV (-5%), our novel method presented 80-90% efficiency of SNAP+25 isolation (FIG. 5C). Nano-flow cytometry confirmed -85% of the isolated NDE were positive for SNAP -25, and -60% of NDE were also positive for validation marker synaptophysin (FIG. 5C-right panel).
[0084] Isolated NDEs from plasma represent high concordance in cargo with brain tissue and brain tissue-derived sEV. To confirm that the isolated NDEs from plasma are indeed sEV from brain tissues, we isolated total RNA from above mentioned three different brain tissues from control and AD (n=12 each) and sEV isolated from these brain tissues (described in FIG. 2). We also isolated NDEs from plasma of another cohort of control and AD (n=28 each). All samples were analyzed for the expression of miR-342-3p. We identified that the brain tissue, their sEV, and plasma NDEs from AD individuals represents similar directional change (increase) of miR-Atty. Dkt. No. 186563.00009342-3p expression (FIG. 6A-6C). Next, we further confirmed that the miRNA expression in brain tissue and their corresponding brain tissue-derived sEV follow the same pattern in control and AD by generating Bland-Altman plots comparing miR-342-3p expression. Results demonstrated that miR-342-3p expression shows high concordance between the parent brain tissue and their sEV (FIG. 6D).
[0085] NDEs highlight the differential levels of protein biomarkers in dementia. To assess the utility of SNAP-25+ NDEs in identifying the differences based on typical AD related biomarkers, we utilized plasma from control, mild cognitive impaired (MCI), and AD individuals (n=10 each) and characterized for 120+ target proteins simultaneously with ultra- high sensitivity sing NULISAseq platform. The data showed differential expression of various proteins related to neuro-inflammation and neurodegeneration markers among control, MCI and AD (FIG. 7), establishing the feasibility to use this technology for the proposed NDE characterization.
[0086] The detailed methodology is described below:
[0087] Identification of additional neuron and other brain cells-specific sEV surface markers. In the feasibility study, we identified SNAP -25, GPM6A, BTBD17, and GABRA1 as specific markers on the surface of NDEs from the mass spectrometry data collected from three different brain regions of control and AD individuals (n=12 each, total n=24). The data is being further analyzed to identify more neuronal sEV markers; and markers specific to other brain cell types, and different brain regions. We are applying a deconvolution approach to the mass spec data to identify sEV specific surface markers, either exclusively present or enriched on different brain cells including neurons.
[0088] Perfecting the total sEV isolation by “On-Target” approach. The workflow of “On-Target brain sEV Capture” method is two-step process; 1. Isolation of pure total sEV. 2. Isolation of NDEs from total sEVs. In completed studies, we optimized the major steps for the isolation of total sEV and SNAP+ NDEs, the slight inconsistencies observed in preliminary studies will be addressed in this application. For example, after filtration through 0.22pm filter, sEV will be subjected to precise DNase, RNase, and proteinase treatment to remove non- sEV DNA, RNA, and proteins, followed by loading to specific 300KDa molecular cutoff columns (FIG. 8).Atty. Dkt. No. 186563.00009
[0089] All non-sEV associated biomolecules will be passed through the columns leaving the pure total sEV in the upper column for recovery (FIG. 8). Furthermore, we have identified several Go or No-Go points emphasizing the validity of isolated sEV and any measures required to rectify the concerning step / s (FIG. 9). For example, after passing the sequentially centrifuged plasma / serum samples through 0.22pm filter, we will label an aliquot with a lipid membrane dye and acquire the samples on nano-flow cytometry. In case of presence of bigger sized particles, samples will be passed again through a fresh 0.22pm filter with low force. Similarly, the flow through of the 300KDa filtrate will be analyzed by a similar approach for any possible loss of total sEV. If more than 5% of the sEV were found in flow through, the centrifugation force and time will be optimized (FIG. 9).
[0090] Isolation of NDEs from total sEV. As shown in the preliminary data and reported earlier, we have successfully isolated NDEs using SNAP -25. Based upon our brain sEV surface proteome data, along with SNAP-25, we have included GPM6 A, BTBD17, andGABRAl as surface markers to improve the specificity, yield and intact NDEs recovery. This panel of NDE specific surface markers are used either to pullout NDEs and confirm their purity following isolation. Further, our novel workflow reduces the loss of NDE by specific filters, which allows the binding, washing, and elution of NDEs on filters. The pore size of the filter does not allow the agarose beads to pass through, however the non-target unbound (to antibody and agarose beads) sEV pass through these filters. The beads-antibody bound NDE are washed on column and eluted by adding low pH elution buffers (FIG. 10). The completed data suggested that the SNAP+ NDEs constitute ~5% of the total sEV, while the current approach yielded ~4% SNAP+ NDEs from the total sEV in terms of concentration / number based on NTA (80-90% recovery); we have further titrated total sEV and antibodies concentration (SNAP -25, GPM6A, BTBD17, and GABRA1), and antibody to streptavidin coated beads ratio to increase the recovery of NDEs from total sEV.
[0091] Deliverable. “On-Target Brain sEV Capture” is being developed as a commercial kit which will provide pure, specific, and reproducible brain specific sEV isolation. We are confident that the “On-Target Brain sEV capture” will be well received by the research community working in EV field and will help in expediting the transition of sEV based biomarkers for ADRD from laboratory to clinic.Atty. Dkt. No. 186563.00009Example 2 - A Brain Informed Surface Marker Panel Enables Robust Isolation of Neuron Derived Extracellular Vesicles from Human Plasma
[0092] Isolation of neuron-derived small extracellular vesicles (NDE) from peripheral biofluids offers a promising approach to access brain-specific molecular information. However, this has been limited by the lack of well-validated, disease-independent surface markers. In this study, we developed and validated a brain-informed strategy for the specific and robust isolation of NDE from human plasma. Using small extracellular vesicles (sEV) isolated from multiple postmortem human brain regions with differential vulnerability to Alzheimer’s disease (AD), including frontal cortex, middle temporal gyrus, and cerebellum, we conducted surface-focused proteomic analyses to identify neuronal membrane proteins consistently present across regions and disease states. This approach prioritized four surface markers, BTBD17, GABRA1, GPM6A, and SNAP-25, which were subsequently used for immuno-based isolation of NDE from plasma. Plasma-derived NDE isolated using this marker panel exhibited size, morphology, and molecular characteristics consistent with sEV, as confirmed by nanoparticle tracking analysis, transmission electron microscopy, super-resolution microscopy, immunogold labeling, and nano-flow cytometry. The neuronal specificity and purity of the isolated vesicles were further validated by detection of multiple independent neuronal markers. Transcriptomic analysis of NDE from cognitively normal, mild cognitive impairment (MCI), and clinical intervention cohorts demonstrated that their RNA cargo was predominantly neuronal in origin and biologically informative. Both total RNA sequencing and NanoString-based miRNA profiling revealed a broad reduction in neuronal transcription in NDE from MCI individuals.
[0093] Importantly, application of this isolation strategy to samples from a dietary intervention study demonstrated consistent NDE yield and size distribution across dietary conditions and longitudinal sampling, supporting methodological robustness in clinical settings. Collectively, these findings establish a novel, disease-independent, multi-marker method for isolating neuron-derived sEV from plasma that yields highly pure vesicles carrying meaningful neuronal molecular signatures, with broad applicability for biomarker discovery and translational neuroscience.
[0094] IntroductionAtty. Dkt. No. 186563.00009
[0095] Alzheimer's disease (AD) is a multifactorial neurodegenerative disease that impairs approximately 6.9 million Americans aged 65 and older. Moreover, the World Health Organization estimates that 55 million global citizens possess dementia with a projected rise to 139 million within 30 years. Although the characteristic features of the AD brain are pathological protein formations, known as amyloid beta plaques and neurofibrillary tau tangles, we still have a limited understanding of the molecular underpinnings that promote the disease onset and progression. This lack of molecular information underscores unexplained AD-related phenomena such as the sex-specificity of the disease, proteinopathic resistant individuals, and the role of dysregulated brain insulin signaling.
[0096] Since the recent multitude of studies demonstrating EVs critical involvement in homeostatic and pathogenic intercellular communication there has been a burgeoning interest in their cargo as biomarker sources (Hill, 2019; You & Ikezu, 2019). Consequently, EVs were poised for their potential as noninvasive biomarkers in neurodegenerative diseases as in vivo brain tissue is intractable to direct experimental interrogation of molecular changes. Comprehensive evaluation of tissue- and biofluid-isolated neuron-derived small extracellular vesicles (NDEs) has substantiated the diagnostic capacity of EVs to distinguish not only physiological from pathological status, but their disease-specific molecular profiles also discriminate distinct neurodegenerative diseases from one another (Fiandaca et al., 2015). NDE isolated from plasma have been found to possess AD-specific markers, such as A01-42, p-S396-tau, and p-T181-tau which could discriminate AD subjects from case controls (Fiandaca et al., 2015). Kapogiannis et al. 2015 uncovered a significant association between altered insulin receptor substrate 1 (IRS-1) phosphorylation in plasma NDE and increased brain insulin resistance in Alzheimer's disease patients, distinguishing them from those with type 2 diabetes or frontotemporal dementia. Their NDE phospho (P) serine-IRS-1 and P-tyrosine-IRS- 1 levels predicted AD development up to 10 years in advance, implying a unique link between insulin signaling disruption and AD (Kapogiannis et al., 2015). Following this, Mullins et al. 2017 found that these same biomarkers correlated with regional brain atrophy in AD, again supporting the role of brain insulin resistance in AD pathogenesis and the diagnostic potential of neural-origin plasma sEV (Mullins, Mustapic, et al., 2017). While these investigations have relied on L1CAM, some EV researchers have decided to begin directly characterizing the surface markers on sEV. You et al., 2022 (You et al., 2022), Mishra et al., 2023 (Mishra et al., 2023), and Abdelmohsen et al., 2023 (Abdelmohsen etAtty. Dkt. No. 186563.00009al., 2023) have all begun to experimentally define the surface protein markers of various tissue-and plasma-derived sEV to improve the specificity of existing immuno-capture methods. Although L1CAM is predominantly utilized, and its presence on NDE has since been confirmed, it was initially used as a putative marker based on the predominantly neuronal distribution noted in the Allen Brain Atlas. Other putative NDE markers have been selected in a similar manner, which is not supported by the direct experimental interrogation of NDE surface proteomes. Unfortunately, there are no extensive databases which have compiled human EV surface proteomes.
[0097] Investigations of biofluid brain cell-derived sEV have prominently featured neuron-derived EVs (NDE), with significantly less attention to EVs originating from astrocytes, microglia, and endothelial cells (Abdelmohsen et al., 2023; Kumar et al., 2023; Valle-Tamayo et al., 2022; Visconte et al., 2023). While multiple markers have been utilized to enrich NDE subpopulations from biofluids, such as plasma, LI cell adhesion molecule (LI CAM or CD 171) stands out as the most employed NDE surface marker (Pulliam et al., 2019). L1CAM is a transmembrane protein that has an extracellular domain critical for cell adhesion and an intracellular domain associated with signaling (Samatov et al., 2016). Yet, despite its widespread use, there are concerns regarding the specificity and sensitivity of isolating NDE using L1CAM (Norman et al., 2021). L1CAM is not exclusive to neurons as it is also present in other brain cells and peripheral tissues such as the kidneys and bladder. Additionally, the protein is prone to cleavage which creates soluble L1CAM peptides that can interfere with NDE-associated enrichment and biomarker detection methods (Norman et al., 2021; Sugawa et al., 1997). Nonetheless, ample evidence supports not only the presence of L1CAM on the surface of NDE, but it has also proven to be a robust target for neurological disease biomarker development in peripheral biofluids (Kumar et al., 2021, 2022, 2023). To enhance the specificity of neuron-derived origins of NDE, some researchers have adopted the use of additional neuronal-enriched surface protein markers alongside LI CAM, such as synaptophysin (SYP), in their methodologies. Elowever, the disputation that NDE do not possess LI CAM surface proteins does reflect a crucial gap in the EV field: there are currently no cell, tissue, or organ-specific sEV surface proteome signatures, defined by experimentation, that researchers can employ to selectively target subpopulations of EVs from complex biofluids like plasma.Atty. Dkt. No. 186563.00009
[0098] EVs are released by every known cell type into systemic circulation; therefore, given there are multiple methods to isolate EVs and they are readily accessible in biofluids, like blood, they represent suitable candidates for biomarker discovery. Furthermore, EV cargos reflect the physiological status of their parent cells as snapshots of cytosolic content (De Toro et al., 2015). Accordingly, EVs have been recommended as liquid biopsies for diseases that impact organs like the brain which are both difficult to access and unsuitable for tissue biopsy. Here we characterize the surface proteome of brain-region specific-sEV and strengthening the utility of biofluid brain- derived sEV as a minimally invasive approach to identify the molecular changes underlying brain insulin resistance and Alzheimer’s disease, and their concomitance.
[0099] In the present investigation, we isolated sEV from the frontal cortex, middle temporal gyrus, and cerebellum of severe Alzheimer’s disease (AD) human subjects and age- and sex- matched controls. We interrogated the surface proteome of the sEV from each region using a novel surface shaving methodology with subsequent global proteomic mass spectrometry analysis. This method employs a trypsin digest of the sEV which enables separation of the sEV core, which is the intact lipid bilayer with biomolecular cargo, from surface proteins. Our data demonstrate that not only are there conserved surface proteins on the sEV isolated from each of the three brain regions, but there are also unique proteins that may be used to distinguish them. Furthermore, there were AD-specific changes in each brain region sEV surface proteome that suggest the surface peptides may also reflect a disease specific proteomic signature unique to each brain region.
[0100]
[0101] Methods
[0102] Study Participants and Clinical Data
[0103] Frozen archived human brain tissue (frontal cortex, middle temporal gyrus, and cerebellum) from twelve severe AD cases (n = 6 female, n = 6 male) and twelve age- and sex- matched control cases (n = 6 female, n = 6 male) were obtained from the University of Washington Alzheimer’s Disease Research Center (UW ADRC). Subjects were selected based on the severity of Alzheimer’s disease (AD)-associated pathological features with minimal -to-none non- AD dementia pathology: amyloid plaque burden, neurofibrillary tau tangles, and overall ADAtty. Dkt. No. 186563.00009pathological score. Control subjects were selected by the absence of AD-associated pathological change. The demographic information including sex, age-at-death, postmortem interval (PMI), Thai staging, Braak staging, CERAD scoring, and overall AD neuropathological changes are outlined in Table 1. All activities described were approved by the Wake Forest Institutional Review Board and conducted in accordance with the Helsinki Declaration of 1975.
[0104] Isolation of Brain Tissue-Derived sEV (BDE)
[0105] We employed a gentle tissue dissociation method, modified from Vella et al., 2017 (Vella et al., 2017) to reduce cell lysis and production of non-vesicular small particles, thus isolating predominantly sEV. Frozen (-80°C) human frontal cortex, middle temporal gyrus, and cerebellum brain tissues (334 mg- 1125 mg) were each weighed in a petri dish before being sliced into lengthwise sections on ice. Sliced brain sections were transferred into 15 mL conical tubes containing Hibernate-E media, at 800pL per 100 mg of tissue, and 75 U / mL of collagenase type III. The conical tubes were then placed in a 37°C shaking water bath for 30 minutes. After 30 minutes, the tissues were pipetted up-and-down using a P1000 pipette with wide bore tip. Samples were then put on ice before adding protease and phosphatase inhibitor cocktail in Hibemate-E to each sample at a final concentration of lx. The final volumes of each sample were made the same with the addition of the inhibitor cocktail in Hibernate-E.
[0106] All spins were performed in a refrigerated centrifuge at 4°C and all PBS was filtered with 0.1 pm filter, unless otherwise stated. Collagenase type III dissociated tissue was then centrifuged for 5 minutes at 300 x g. The tissue pellet, now depleted of sEV, was collected, and split into two smaller tissue pellets for DNA / RNA isolation (pellet 1) and protein isolation (pellet 2) to be stored at -80°C until processed. The supernatant was transferred to a clean 15 mL conical and centrifuged at 2,000 ' g for 10 minutes, then the supernatant was transferred to a 50 mL conical tube and spun at 10,000 x gfor 30 minutes. Before the ultracentrifugation steps, all supernatants were filtered at 0.22 pm, then brought to a final volume of 35 mL with the addition of PBS. The 35 mL supernatants were laid atop 3 mL of 30% sucrose cushions (sucrose was dissolved in deuterium oxide and the solution was filtered with 0.1pm filter) and spun at 100,000 x g for 90 minutes. 2 mL of the 30% sucrose cushion was collected, dissolved in an additional 6 mL of PBS and spunAtty. Dkt. No. 186563.00009at 100,000* g for 90 minutes. The supernatant was removed and the resulting sEV pellets were resuspended in 200 pL of PBS.
[0107] Nanoparticle Tracking Analysis
[0108] sEV size and concentration were analyzed by nanoparticle tracking analysis (NTA) using the Nanosight NS300 (Malvern Instruments, UK), as previously outlined. Five videos, each 30 seconds, were recorded for every sample, and each sample sEV size and concentration was represented by the average of all videos per sample.
[0109] Immunogold Labeling
[0110] For immuno-gold (IG) labeling, sEV were adsorbed for 1 hour to a carbon-coated grid after being fixed with 2% paraformaldehyde in PBS buffer (pH 7.4). To evaluate the presence of typical sEV surface markers, the sEVs were incubated with CD63 and CD81 primary antibodies. To retain maximum sEV quantity for surface shaving, we pooled two aliquots from all of the samples used for IG for CD63 and CD81 negative controls. For the negative control we used no primary antibody but included gold-labeled secondary antibody. A secondary antibody tagged with 10 nm gold particles was subsequently used, and images were captured on a Tecnai T12 transmission electron microscope (TEM).
[0111] Analyses of BDE Surface Proteins
[0112] The surface protein on the isolated BDE was shaved as reported by us recently. BDE were incubated with mild trypsin at 37°C for 2 hours. Digestion was then quenched by adding 10% formic acid. The mixture was centrifuged at 200,000g for 2 hours to recover shaved-BDE (pellet) and their surface proteins (supernatant). For MS analysis, 100 pl of 2x RIPA buffer containing 2x protease inhibitor cocktail was added to the suspension. Proteins were reduced and alkylated with the presence of lOmM dithiothreitol and 30mM iodoacetamide. Four times the sample volume of cold acetone was added to the tube, and then incubated at -20°C overnight. The protein pellet was obtained by centrifugation at 14,000g for 10 minutes at 4°C, and the supernatant was discarded. Surface proteins were analyzed on a liquid chromatography tandem mass spectrometry (LC- MS / MS) system consisting of an Orbitrap Eclipse Mass Spectrometer (Thermo Scientific, Waltham, MA) and a Vanquish Neo nano-UPLC system (Thermo Scientific, Waltham, MA).Atty. Dkt. No. 186563.00009Peptides were separated on a DNV PepMap Neo (1500 bar, 75 pm x 500 mm) column for 120min employing linear gradient elution consisted of water (A) and 80% acetonitrile (B) both of which contained 0.1% formic acid. Data were acquired by top speed data dependent mode where maximum MS / MS scans were acquired per cycle time of 3 seconds between adjacent survey spectra. Dynamic exclusion option was enabled which duration was set to 120 seconds. To identify proteins, spectra were searched against the UniProt human protein FASTA database (20,309 annotated entries, Jun 2021) using the Sequest HT search engine with the Proteome Discoverer v2.5 (Thermo Scientific, Waltham, MA). Search parameters were as follows: FT-trap instrument; parent mass error tolerance, 10 ppm; fragment mass error tolerance, 0.6 Da (monoisotopic); enzyme, trypsin (full); # maximum missed cleavages, 2; variable modifications, +15.995 Da (oxidation) on methionine. All assembled proteins with peptide spectrum match (PSM) counts were quantified and normalized using the normalized spectral abundance factors (NSAFs) to determine their relative abundance.
[0113] To evaluate the expression of brain region-specific surface proteins, we employed criteria to reduce the likelihood of underrepresented proteins. First, each brain region must have a >2 PSM for at least half of the subjects (minimum n = 6) in the healthy and AD conditions. Then average PSM was determined for both healthy and AD samples so that we could produce a ratio of the PSM (healthy PSM / AD PSM). All proteins meeting the criteria were then ranked based on their PSM ratio; only proteins whose ratio was 0.8 - 1.2 were accepted as stably expressed sEV surface proteins. In this fashion we are only including surface proteins that would be no greater or lesser than 20% in either healthy or AD condition sEV. These criteria were to determine sEV surface markers for each brain region that can be utilized in both healthy and AD subjects. The purpose of the ratio range was to avoid selecting any surface peptides which may be enriched, or exclusive, to one health condition and thus not useful as a biomarker across the disease continuum.
[0114] Conversely, to determine the expression of brain region-specific surface proteins enhanced by AD, we utilized another set of criteria. First, each brain region and each health condition much have a >2 PSM for at least half of the subjects (minimum n = 6). However, we only accepted proteins that were present in n < 3 healthy subjects while n > 6 in AD subjects; each subject was only counted if their PSM for that specific protein was >2. These criteria wereAtty. Dkt. No. 186563.00009employed to determine if there are AD-specific sEV surface proteomic changes that can represent novel biomarkers themselves.
[0115] Isolation of NDE from plasma
[0116] Total sEV and NDE were isolated from plasma using the methodology as recently published by us {Kumar, 2022 #1}. Briefly, plasma samples from all participants were processed using our modified precipitation method to isolate total sEV {Kumar, 2023 #37; Kumar, 2022 #1; Kumar, 2021 #36}. For the isolation of NDE, 1000 pg of total sEV were incubated overnight at 4°C with continuous mixing with 2 pg of each specific biotin-labeled antibodies; BTBD17, GAB RAI, GPM6A, SNAP-25. Further, 40 pl of streptavidin-coated magnetic beads (ThermoFisher, Cat. No. 88817) were washed once with 400 pl of washing buffer (0.2 micron filtered tris buffered saline + 0.1% Tween-20) and resuspended in the 100 pl of resuspension buffer (0.2 micron filtered PBS + 1% BSA) before adding to the sEV-antibody suspension for 1 hr incubation at room temperature with continuous mixing. The beads were then washed 3 times with the washing buffer. For the elution of NDE, beads were resuspended in 200 pl of gentle Ag / Ab elution buffer (ThermoFisher, Cat. No 21027, pH 6.6) for 10 min. Beads were magnetized and removed and eluted NDE were transferred to a new tube containing 10% v / v IM Tris (pH=9) to neutralize the pH of the elution buffer.
[0117] Transcriptomics analysis of NDE
[0118] Total RNA from NDE was isolated by mixing NDE with Trizol reagent directly for 10 min incubation at RT with intermittent vortexing. Following incubation, 100 pl of chloroform was added to the tube and mixed. Tubes were centrifuged for 1 min at 14,000* g at 4°C. The top clear layer was recovered, and after the addition of 2-3 vol of 100% ethanol, incubated at -80 °C for 2 hrs. RNA was further washed and eluted (in 22 pl of RNase free water) using and following the recommendation of RNAeasy mini kit (Qiagen, Maryland, USA).
[0119] Cap-WTS library preparation and sequencing
[0120] The Capture-based whole transcriptome sequencing (WTS) library prep was performed at Burning Rock Dx, Irvine, CA, US. Briefly, EV RNA was reverse transcribed to cDNA. Biotinylated RNA baits were hybridized to the synthesized cDNA targets, and the bait -targetAtty. Dkt. No. 186563.00009complexes were amplified in a postcapture polymerase chain reaction (PCR) reaction. Final libraries of cap-WTS were quantified using QubitTM dsDNA HS assay (Thermo Fisher, Carlsbad, CA, US). After library size-distribution determined by using the Agilent TapeStation (Agilent Technologies, Santa Clara, CA, US), the libraries were sequenced on NovaSeq 6000 sequencer (illumina, San Diego, CA, US) with 2 x 150 bp pair-end reads.
[0121] Cap-WTS data analysis
[0122] The raw reads were trimmed with trimmomatic (v0.36) and trimmed reads were processed with UMI information by in-house scripts to generate consensus reads. Then the consensus reads were aligned against the human reference genome (hgl9) by STAR (v2.7.3a). Gene and transcript level quantification (TPM) was performed using Salmon (vl.2.1).
[0123] miRNA analysis using nCounter (NanoString)
[0124] Total RNA was analyzed using the NanoString nCounter miRNA Expression Assay according to the manufacturer’s instructions. Briefly, equal amounts of RNA were subjected to miRNA-specific tag ligation followed by hybridization to reporter and capture probes. Samples were processed on the nCounter Prep Station and scanned on the nCounter Digital Analyzer to obtain raw digital counts. Data quality control, background correction, and normalization were performed using nSolver Analysis Software. Counts were background corrected using negative controls and normalized to positive controls and either the global mean of expressed miRNAs or selected reference miRNAs. Normalized data were log2 transformed, and differential expression analysis was performed within nSolver using default statistical settings, with multiple testing correction applied where indicated.
[0125] Results
[0126] Isolation and Characterization of Brain Tissue-Derived sEV (BDE)
[0127] First, we isolated sEV from the frontal cortex, middle temporal gyrus, and cerebellum of fresh frozen human brain tissue (FIG. 14). To confirm the presence of conventional sEV surface markers (CD63, and CD81) on the surface of frontal cortex, middle temporal gyrus, and cerebellum tissue-derived sEV we performed immunogold labeling and subsequent transmissionAtty. Dkt. No. 186563.00009electron microscopy (TEM) (FIG. 15A). Black dots on the sEV represent positivity for either CD63 or CD81, accordingly. Furthermore, Golgi matrix protein 130 (GM130) and cytochrome c (CYCS), markers considered to indicate parent tissue protein contamination (MISEV 2023), were absent in all three brain region sEV surface marker proteomes. Finally, nanoparticle tracking analysis (NTA) exhibited no significant difference between the mean size and the concentration of sEV between each brain region or between health statuses in each region (healthy vs. AD) (FIG.15B-C). Our mean sEV sizes ranged between 167nm - 176nm, an acceptable range for sEV (< 200nm) as defined by MISEV 2023 {Welsh, 2024 #6}. The concentration of sEV was not significantly different between brain regions or between health conditions within the same brain region. Although we considered normalizing sEV concentration to tissue mass, we determined that based on our samples this may provide inconsistent results. Many of our brain tissues exhibited varying amounts of gray matter-to- white matter ratios; thus, comparisons of tissue mass to sEV concentration may be convoluted by the composition of each tissue.
[0128]
[0129] Identification of Unique Brain Tissue-Derived sEV Surface Proteins
[0130] We investigated the surface proteome of the sEV isolated from the frontal cortex, middle temporal gyrus, and cerebellum by implementing our established surface shaving method and subsequent LC-MS / MS. Brain tissues were processed to isolate sEV using a modified version of the method by Vella et al., 2018 (FIG. 14). Our surface shaving method enables us to separate the surface protein peptides from intact sEV cores, which contain their own proteome distinct from the surface, by ultracentrifugation after the whole tissue-derived sEV are incubated with trypsin. Optimization of this protocol was previously performed by our lab as reported by Mishra et al., 2023 {Mishra, 2023 #19}. Using zeta potential, NTA, immunogold labeling, and nano-scale flow cytometry we previously demonstrated that the surface shaving protocol did not compromise the integrity of the lipid bilayer but did successfully reduce the presence of sEV surface proteins on the intact membranes.
[0131] The unique and common proteins isolated from the frontal cortex, middle temporal gyrus, and cerebellum sEV are represented in a Venn diagram (FIG. 16). We conducted a protein abundance analysis between healthy and AD subjects by evaluating the peptide-spectrum matchAtty. Dkt. No. 186563.00009(PSM) ratios for each identified protein, calculated as the average healthy PSM divided by the average AD PSM. We applied a defined threshold that considered proteins with no more than a ±20% change, producing PSM ratios within the range of 0.8-1.2. This assessment included six acknowledged extracellular vesicle markers: programmed cell death 6-interacting protein (PDCD6IP / ALIX), tumor susceptibility gene 101 (TSG101), syntenin 1 (SDCP), flotillin 1 (FLOT1), flotillin 2 (FLOT2), and CD81, consistent with the criteria set out in MISEV 2023. Notably, two other recognized markers, CD9 and CD63, were absent from our data. Our findings revealed a significant enrichment of TSG101 in the Alzheimer's disease frontal cortex (p=0.003) and cerebellum (p=0.036) sEV surface proteomes. However, this enrichment was not observed in the middle temporal gyrus. SDCP displayed a significant reduction in the AD frontal cortex (p=0.002) and middle temporal gyrus (p<0.001), with no significant change detected in the cerebellum. FLOT1 maintained consistent levels across healthy and AD subjects within the frontal cortex and middle temporal gyrus, yet it was significantly elevated in the AD cerebellum (p=0.028). FLOT2 showed no significant variation across all brain regions studied. Interestingly, both ALIX and CD81 levels did not display changes in the AD frontal cortex and middle temporal gyrus sEV surface proteomes, but both markers demonstrated significant enrichment in the AD cerebellum sEV surface (p<0.001 and p=0.001, respectively). These findings highlight the complex nature of tissue-derived sEV surface proteins as biomarkers. Despite the consensus in the field regarding the presence of these markers across EVs, our study illustrates that their abundance is not merely altered by Alzheimer's pathology but also exhibits a pronounced regional specificity within the human brain.
[0132]
[0133] sEV surface proteomes demonstrate conserved and unique proteins between brain regions and reflect Alzheimer’s disease specific changes
[0134] From MS analysis, we observed that the cerebellum sEV yielded more identifiable sEV surface proteins followed by frontal cortex, then middle temporal gyrus (FIG. 16A-B). We identified 880 sEV surface proteins in the cerebellum, 508 in the frontal cortex, and 264 in the middle temporal gyrus (FIG. 16). Notably, among those proteins unique to each region, we identified 605 in the cerebellum, 179 in the frontal cortex, and 56 in the middle temporal gyrusAtty. Dkt. No. 186563.00009(FIG. 16A). However, there were 90 total proteins that were shared between all three regions’ sEV surface proteomes.
[0135] Further, we determined the AD-specific proteomic changes to the sEV surface from three brain regions. We only accepted proteins that were present in n < 3 healthy subjects while n > 6 in AD subjects, while the PSM for that specific protein was >2. These criteria were employed to determine if there are AD-specific sEV surface proteomic changes that can represent novel biomarkers themselves. We observed that there were fewer conserved proteins between each region when considering those surface proteins that were disproportionately present in AD conditions. Furthermore, in this data set there were no proteins that were conserved between all three brain regions, suggesting that the AD-specific changes exhibit regional molecular specificity. We identified 165 proteins in the cerebellum, 17 in the frontal cortex, and 29 in the middle temporal gyrus (FIG. 16B). Within the identified proteins, 158 in the cerebellum, 13 in the frontal cortex, and 22 in the middle temporal gyrus were unique to their respective brain regions; 2 proteins were shared between frontal cortex and cerebellum, 5 between middle temporal and cerebellum, and 2 between the middle temporal gyrus and frontal cortex.
[0136] Discovery of Novel sEV Surface Proteins Originating from Brain Tissue
[0137] There are currently two community annotated databases compiling molecular information on EVs: Vesiclepedia and ExoCarta. While Vesiclepedia contains data from all EV subtypes, ExoCarta exclusively reports data from exosomes, which do overlap in size with sEV. Both databases contain information on lipid, protein, metabolite, and nucleic acid cargo in the EV subtypes which they relate to. Because these databases possess sEV proteomic information, we sought to compare those proteins which we identified using our method to those reported by the larger EV research community.
[0138]
[0139] However, to compare our datasets against the two databases, we decided to implement a larger list of identified surface proteins from our three brain regions’ sEV. These lists were all proteins whose PSM was >2 in at least 6 healthy and 6 AD subjects for each given protein; however, we did not exclude proteins whose H / AD ratio was outside of the 0.8 - 1.2 range. Comparing ourAtty. Dkt. No. 186563.00009dataset against Vesiclepedia, we found that we identified 56, 4, and 63 proteins in the cerebellum, middle temporal gyrus, and frontal cortex, respectively, that were not already in their database (FIG. 17A). Alternatively, we found that ExoCarta reported even fewer shared sEV proteins with our data; our data exhibited 120 unique cerebellum proteins, 6 unique middle temporal gyrus proteins, and 131 unique frontal cortex proteins (FIG. 17B).
[0140] Next, we identified the common proteins between at least two brain regions, which are not altered by more than 20% in control vs AD conditions. In those proteins we then searched the Human Proteins Atlas for brain neurons enriched proteins and identified the common proteins. We identified BTBD17, GABRA1, GPM6a, and SNAP-25 as brain neurons specific proteins which are not affected by the disease condition and can be used for NDE isolation from plasma.
[0141] Characterization of Plasma NDE isolated using novel markers
[0142] NDE were isolated from human plasma using biotin-tagged antibodies against four neuronal surface proteins identified from brain-derived sEV proteomic profiling. Nanoparticle tracking analysis demonstrated that the isolated NDE displayed a size distribution consistent with small extracellular vesicles, with a major population centered below 150 nm, and comparable particle concentrations across samples (FIG. 18A). Protein quantification showed no significant difference in total protein content between control and AD groups (FIG. 18B).
[0143] Transmission electron microscopy revealed round, membrane-bound vesicles with morphology consistent with sEV (FIG. 18C). Super-resolution microscopy further confirmed the presence of neuronal surface markers on individual vesicles, along with canonical exosomal markers including CD9 and CD63 (FIG. 18D). Immunogold labeling followed by TEM demonstrated surface localization of BTBD17, GABRA1, GPM6A, and SNAP-25 on isolated NDE, supporting their accessibility and suitability as capture markers (FIG. 18E).
[0144] Nano-flow cytometry analysis showed robust surface expression of BTBD17, GABRA1, GPM6A, and SNAP-25 on the isolated vesicle population (FIG. 19, upper panel). Additional validation using commonly used neuronal markers, including L1CAM, ATP1A3, NCAM, and SYP, further supported the neuronal specificity and purity of the isolated NDE (FIG. 19, lowerAtty. Dkt. No. 186563.00009panel). Collectively, these results confirm successful isolation of pure and specific NDE from plasma using disease-independent neuronal surface markers.
[0145]
[0146] RNA Cargo and Transcriptomic Profiling of Plasma-Derived NDE
[0147] NDE isolated from plasma of cognitively normal and mild cognitive impairment (MCI) individuals were subjected to total RNA sequencing to assess RNA cargo composition and disease- associated changes. Deconvolution analysis of the RNA-seq data demonstrated that the majority of transcripts detected in NDE were of neuronal origin, with minimal contribution from non-neuronal cell types (FIG. 20A), confirming the neuronal specificity of the isolation strategy.
[0148] Differential expression analysis revealed a marked predominance of downregulated transcripts in NDE from MCI individuals compared with cognitively normal controls (FIG. 20B). Volcano plot visualization highlighted a broad reduction in mRNA abundance in MCI-derived NDE, with relatively few transcripts showing increased levels (FIG. 20C).
[0149] Gene ontology analysis of the downregulated mRNAs identified significant enrichment of pathways related to RNA metabolism and transcriptional regulation, including ncRNA-mediated gene silencing, transcription elongation, RNA localization, and nucleic acid transport (FIG. 20D). Additional affected processes included protein-containing complex disassembly and nuclear transport. Together, these data indicate that NDE from MCI individuals exhibit a global reduction in neuronal RNA cargo, with preferential involvement of pathways associated with transcriptional control and RNA processing.
[0150] miRNA Profiling of Plasma-Derived NDE by NanoString nCounter:
[0151] The same total RNA isolated from plasma-derived neuron-derived sEV (NDE) from cognitively normal and MCI individuals was further analyzed for the expression of 827 human miRNAs using the NanoString nCounter platform. Overall miRNA expression profiles showed high reproducibility across samples, with a strong correlation between control and MCI groups, although global miRNA abundance was reduced in NDE from MCI individuals (FIG. 21A).Atty. Dkt. No. 186563.00009
[0152] Differential expression analysis identified a limited subset of miRNAs that were significantly altered between groups. Most significantly changed miRNAs exhibited reduced expression in NDE from MCI individuals, while only a small number showed increased levels (FIG. 2 IB). Several downregulated miRNAs reached statistical significance with a fold change greater than two, whereas a few upregulated miRNAs were also detected but to a lesser extent.
[0153] Collectively, these data indicate that, similar to mRNA cargo, the miRNA content of plasma-derived NDE is broadly reduced in MCI, suggesting early and widespread alterations in neuronal RNA packaging or stability associated with cognitive impairment.
[0154] Validation of NDE Isolation in the BEAT-AD Clinical Cohort
[0155] To further assess the robustness and translational applicability of the identified neuronal surface markers, NDE were isolated from plasma samples obtained from participants enrolled in the BEAT-AD (Brain Energy for Amyloid Transformation in Alzheimer’s Disease) study. NDE isolation was performed using the same four-marker panel, across samples collected before and after dietary intervention with either a Modified Mediterranean Ketogenic Diet (MMKD) or the American Heart Association Diet (AHAD).
[0156] Nanoparticle tracking analysis demonstrated that NDE isolated from all conditions exhibited a consistent size distribution within the expected range for small extracellular vesicles, with no appreciable differences between pre- and post-diet samples or between dietary intervention groups (FIG. 22A). Similarly, particle concentration measurements revealed comparable vesicle yields across all groups, indicating stable recovery of NDE independent of dietary intervention or sampling time point (FIG. 22B).
[0157] These findings further support the reliability and reproducibility of this marker-based isolation strategy across independent clinical cohorts and physiological conditions. Importantly, the consistent size and concentration profiles observed across dietary interventions suggest that NDE isolation using this marker panel is not influenced by metabolic or nutritional state, reinforcing its suitability for longitudinal studies and clinical applications.
[0158] Atty. Dkt. No. 186563.00009
[0159] Di scussion
[0160] A major challenge in the study of neuron-derived extracellular vesicles (NDEs) from peripheral biofluids has been the lack of well-validated, disease-independent surface markers that enable efficient and unbiased isolation. In this study, we addressed this limitation by systematically identifying neuronal surface proteins directly from human brain-derived sEV and subsequently applying these markers for NDE isolation from plasma. Our results demonstrate that BTBD17, GAB RAI, GPM6A, and SNAP -25 together provide a robust and specific strategy for the enrichment of plasma-derived NDE and that vesicles isolated using this approach carry biologically meaningful RNA cargo reflective of neuronal state. The sEV isolated from different brain regions of cognitively healthy and AD individuals, represent the complexities of sEV surface proteomes and their relationship with AD across various brain regions. By employing our novel sEV surface shaving method in conjunction with LC-MS / MS, we have begun to bridge a well- known gap in sEV neuroproteomics, which is to identify unique surface protein signatures from sEV derived from different brain regions, such as the frontal cortex, middle temporal gyrus, and cerebellum.
[0161] Proteomic profiling of sEV isolated from multiple brain regions with distinct vulnerability to Alzheimer’s disease provided a key foundation for marker selection. Importantly, the identified surface proteins were consistently present across frontal cortex, middle temporal gyrus, and cerebellum and were not affected by disease status. This observation is central, as it suggests that these markers label neuronal vesicles irrespective of neurodegeneration and therefore minimize bias toward disease-associated phenotypes. By prioritizing markers with stable neuronal expression, our strategy differs from approaches that rely on single markers or proteins whose expression may change with pathology.
[0162] Using this marker panel, we achieved efficient isolation of NDEs from human plasma with high reproducibility. Multiple orthogonal characterization approaches, including nanoparticle tracking analysis, electron microscopy, super-resolution microscopy, immunogold labeling, and nano-flow cytometry, collectively confirmed that the isolated vesicles fall within the expected size range, display typical sEV morphology, and express established exosomal markers alongside multiple independent neuronal proteins. The detection of additional neuronal markers such asAtty. Dkt. No. 186563.00009LI CAM, ATP1 A3, NCAM, and synaptophysin further supports the neuronal specificity and purity of the isolated NDE population. Together, these data demonstrate that the selected surface markers are accessible on the vesicle surface and suitable for immuno-based capture from plasma.
[0163] Beyond physical and molecular validation, a critical aspect of NDE utility lies in whether their cargo reflects relevant neuronal biology. Transcriptomic analyses addressed this directly. Deconvolution of total RNA-seq data showed that the majority of RNA signatures within NDE were of neuronal origin, indicating minimal contamination from non-neuronal cell types. These findings provide independent functional support for the specificity of the isolation strategy and are consistent with the notion that plasma-derived NDE retain information about neuronal transcriptional states.
[0164] Comparative analysis between cognitively normal and MCI individuals revealed a broad reduction in mRNA abundance in NDE from MCI, with relatively few transcripts showing increased levels. The predominance of downregulated transcripts suggests global alterations in neuronal RNA packaging, transport, or stability at early stages of cognitive impairment. Gene ontology analysis further indicated that affected transcripts were enriched in pathways related to transcriptional regulation, RNA processing, and nuclear transport, pointing toward early disruption of fundamental gene regulatory mechanisms rather than isolated pathway changes.
[0165] Consistent with the mRNA findings, NanoString-based profiling of 827 miRNAs revealed an overall reduction in miRNA abundance in NDE from MCI individuals. Although only a subset of miRNAs reached statistical significance, the global downward shift mirrors the mRNA trends and supports the concept of widespread changes in neuronal RNA cargo during early disease stages. The concordance between mRNA and miRNA data strengthens the conclusion that NDE isolated using this marker set capture biologically coherent and disease-relevant molecular information.
[0166] Collectively, this study establishes a brain-informed, multi-marker strategy for isolating neuron-derived sEV from plasma with high specificity and integrity. By demonstrating that NDE purified using these markers carry transcriptional signatures of neuronal origin and exhibit consistent alterations in MCI, our results support the use of this approach for mechanistic studies and biomarker discovery. Importantly, the disease-independent nature of the markers positionsAtty. Dkt. No. 186563.00009this strategy for broader application across neurodegenerative and neuropsychiatric conditions, where unbiased assessment of neuronal state from peripheral biofluids is critically needed.
[0167] References
[0168] Abdelmohsen, K., Herman, A. B., Carr, A. E., Henry-Smith, C. A., Rossi, M., Meng, Q., Yang, J.-H., Tsitsipatis, D., Bangura, A., Munk, R., Martindale, J. L., Nogueras-Ortiz, C. J., Hao, J., Gong, Y., Liu, Y., Cui, C.-Y., Hartnell, L. M., Price, N. L., Ferrucci, L., ... Gorospe, M. (2023a). Survey of organ-derived small extracellular vesicles and particles (sEVPs) to identify selective protein markers in mouse serum. Journal of Extracellular Biology, 2(8). https : / / doi . org / 10.1002 / j ex2.106
[0169] Abdelmohsen, K., Herman, A. B., Carr, A. E., Henry-Smith, C. A., Rossi, M., Meng, Q., Yang, J.-H., Tsitsipatis, D., Bangura, A., Munk, R., Martindale, J. L., Nogueras-Ortiz, C. J., Hao, J., Gong, Y., Liu, Y., Cui, C.-Y., Hartnell, L. M., Price, N. L., Ferrucci, L., ... Gorospe, M. (2023b). Survey of organ-derived small extracellular vesicles and particles (sEVPs) to identify selective protein markers in mouse serum. Journal of Extracellular Biology, 2(8). https : / / doi . org / 10.1002 / j ex2.106
[0170] Adams, T. E., McKern, N. M., & Ward, C. W. (2004). Signalling by the type 1 insulinlike growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors (Chur, Switzerland), 22(2), 89-95. https: / / doi.org / 10.1080 / 08977190410001700998
[0171] Adzovic, L., Lynn, A. E., D’Angelo, H. M., Crockett, A. M., Kaercher, R. M., Royer, S. E., Hopp, S. C., & Wenk, G. L. (2015). Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. Journal of Neuroinflammation, 12, 63. https: / / doi.org / 10.1186 / sl2974-015-0282-z
[0172] Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., Holtzman, D. M., & Nathan, D. M. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews. Neurology, 14(3), 168-181. https : / / doi . org / 10.1038 / nrneurol .2017.185Atty. Dkt. No. 186563.00009
[0173] Arvanitakis, Z , Wang, H.-Y , Capuano, A. W., Khan, A., Taib, B., Anokye-Danso, F., Schneider, J. A., Bennett, D. A., Ahima, R. S., & Arnold, S. E. (2020). Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function. Annals of Neurology, 88(3), 513-525. https: / / doi.org / 10.1002 / ana.25826
[0174] Athauda, D., Gulyani, S., Kamati, H. K., Li, Y., Tweedie, D., Mustapic, M„ Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., Kapogiannis, D., & Foltynie, T. (2019). Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurology, 76(4), 420-429. https: / / doi.org / 10.1001 / jamaneurol.2018.4304
[0175] Avgerinos, K. I., Mullins, R. J., Vreones, M., Mustapic, M., Chen, Q., Melvin, D., Kapogiannis, D., & Egan, J. M. (2022). Empagliflozin Induced Ketosis, Upregulated IGF- 1 / Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics. Cells, 11(21). https: / / doi.org / 10.3390 / cellsl 1213372
[0176] Avruch, J. (2007). MAP kinase pathways: the first twenty years. Biochimica et Biophysica Acta, 1773(8), 1150-1160. https: / / doi.Org / 10.1016 / j.bbamcr.2006.ll.006
[0177] Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R., & LaFerla, F. M. (2016). Diabetes and Alzheimer’s disease crosstalk. Neuroscience and Biobehavioral Reviews, 64, 272-287. https: / / doi.Org / 10.1016 / j.neubiorev.2016.03.005
[0178] Banzhaf-Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014). MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. The EMBO Journal, 33(15), 1667-1680. https: / / doi.org / 10.15252 / embj.201387576
[0179] Benedict, C., Kern, W., Schultes, B., Born, J., & Hallschmid, M. (2008). Differential sensitivity of men and women to anorexigenic and memory -improving effects of intranasal insulin. The Journal of Clinical Endocrinology and Metabolism, 93(4), 1339-1344. https : / / doi . org / 10.1210 / j c.2007-2606Atty. Dkt. No. 186563.00009
[0180] Blazquez, E., Velazquez, E., Hurtado-Carn eiro, V., & Ruiz-Albusac, J. M. (2014). Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Frontiers in Endocrinology, 5, 161. https: / / doi.org / 10.3389 / fendo.2014.00161
[0181] Boles, A., Kandimalla, R., & Reddy, P. H. (2017). Dynamics of diabetes and obesity: Epidemiological perspective. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(5), 1026-1036. https: / / doi.Org / 10.1016 / j.bbadis.2017.01.016
[0182] Cheung, R., Pizza, G., Chabosseau, P., Rolando, D., Tomas, A., Burgoyne, T., Wu, Z., Salowka, A., Thapa, A., Macklin, A., Cao, Y., Nguyen-Tu, M.-S., Dickerson, M. T., Jacobson, D. A., Marchetti, P., Shapiro, J., Piemonti, L., de Koning, E., Leclerc, I., ... Martinez- Sanchez, A. (2022). Glucose-Dependent miR-125b Is a Negative Regulator of 0-Cell Function. Diabetes, 71(7), 1525-1545. https: / / doi.org / 10.2337 / db21-0803
[0183] Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., & Craft, S. (2015). Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer’s Disease Dementia. Journal of Alzheimer’s Disease : JAD, 45(4), 1269-1270. https : / / doi . org / 10.3233 / JAD-159002
[0184] Courvoisier, B. (1991). [10 years of Central Committee of Medical Ethics], Jahresbericht (Schweizerische Akademie Der Medizinischen Wissenschaften : 1988), 50-68.
[0185] Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., Gessert, D., & Aisen, P. S. (2020). Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: ARandomized Clinical Trial. JAMA Neurology, 77(9), 1099-1109. https: / / doi.org / 10.1001 / jamaneurol.2020.1840
[0186] Davis, J. M., Dickerson, B., Metlay, L., & Penney, D. P. (1991). Differential effects of oxygen and barotrauma on lung injury in the neonatal piglet. Pediatric Pulmonology, 10(3), 157— 163. https: / / doi.org / 10.1002 / ppul.1950100305Atty. Dkt. No. 186563.00009
[0187] De Felice, F. G. (2013). Alzheimer’s disease and insulin resistance: translating basic science into clinical applications. The Journal of Clinical Investigation, 123(2), 531-539. http s : / / doi . org / 10.1172 / JCI64595
[0188] De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009). Protection of synapses against Alzheimer’ s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proceedings of the National Academy of Sciences of the United States of America, 106(6), 1971-1976. https: / / doi.org / 10.1073 / pnas.0809158106
[0189] de la Monte, S. M. (2009). Insulin resistance and Alzheimer’s disease. BMB Reports, 42(8), 475-481. https: / / doi.Org / 10.5483 / bmbrep.2009.42.8.475
[0190] De Toro, J., Herschlik, L., Waldner, C., & Mongini, C. (2015). Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Frontiers in Immunology, 6, 203. https: / / doi.org / 10.3389 / fimmu.2015.00203
[0191] DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique: a method for quantifying insulin secretion and resistance. The American Journal of Physiology, 237(3), E214-23. https: / / doi.Org / 10.1152 / ajpendo.1979.237.3.E214
[0192] Diehl, T., Mullins, R., & Kapogiannis, D. (2017). Insulin resistance in Alzheimer’s disease. Translational Research : The Journal of Laboratory and Clinical Medicine, 183, 26-40. https: / / doi.Org / 10.1016 / j.trsl.2016.12.005
[0193] Ding, L., Yang, X., Xia, X., Li, Y., Wang, Y., Li, C , Sun, Y., Gao, G., Zhao, S., Sheng, S., Liu, J., & Zheng, J. C. (2022). Exosomes Mediate APP Dysregulation via APP-miR-185-5p Axis. Frontiers in Cell and Developmental Biology, 10, 793388. https: / / doi.org / 10.3389 / fcell.2022.793388
[0194] Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012). Insulin in central nervous system: more than just a peripheral hormone. Journal of Aging Research, 2012, 384017. https : / / doi . org / 10.1155 / 2012 / 384017Atty. Dkt. No. 186563.00009
[0195] El Ouaamari, A., Baroukh, N., Martens, G. A., Lebrun, P., Pipeleers, D., & van Obberghen, E. (2008). miR-375 targets 3 ’-phosphoinositide-dependent protein kinase-1 and regulates glucose- induced biological responses in pancreatic beta-cells. Diabetes, 57(10), 2708-2717. https: / / d0i.0rg / l 0.2337 / db07- 1614
[0196] Ferreira, L. S. S., Fernandes, C. S., Vieira, M. N. N., & De Felice, F. G. (2018). Insulin Resistance in Alzheimer’s Disease. Frontiers in Neuroscience, 12, 830. https: / / doi.org / 10.3389 / fnins.2018.00830
[0197] Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., & Goetzl, E. J. (2015). Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 11(6), 600-7. el. https: / / doi.Org / 10.1016 / j.jalz.2014.06.008
[0198] Fu, Y., Hu, X., Zheng, C., Sun, G., Xu, J., Luo, S., & Cao, P. (2019). Intrahippocampal miR-342-3p inhibition reduces 0-amyloid plaques and ameliorates learning and memory in Alzheimer’s disease. Metabolic Brain Disease, 34(5), 1355-1363. https: / / doi.org / 10.1007 / sll011- 019-00438-9
[0199] Gwizdala, K. L., Ferguson, D. P., Kovan, J., Novak, V., & Pontifex, M. B. (2021). Placebo controlled phase II clinical trial: Safety and efficacy of combining intranasal insulin & acute exercise. Metabolic Brain Disease, 36(6), 1289-1303. https: / / doi.org / 10.1007 / sll011-021-00727- 2
[0200] Hallschmid, M., Benedict, C., Schultes, B., Fehm, H.-L., Born, J., & Kern, W. (2004). Intranasal insulin reduces body fat in men but not in women. Diabetes, 53(11), 3024-3029. https: / / doi.org / 10.2337 / diabetes.53.! 1.3024
[0201] Hassing, L. B., Grant, M. D., Hofer, S. M., Pedersen, N. L., Nilsson, S. E., Berg, S., McCleam, G., & Johansson, B. (2004). Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. Journal of the International Neuropsychological Society : JINS, 10(4), 599-607. https: / / doi.org / 10.1017 / S1355617704104165Atty. Dkt. No. 186563.00009
[0202] Health access America. (1990). Kansas Medicine : The Journal of the Kansas Medical Society, 91(4), 92, 95.
[0203] Hill, A. F. (2019). Extracellular Vesicles and Neurodegenerative Diseases. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 39(47), 9269-9273. https: / / doi.org / 10.1523 / JNEUROSCI.0147-18.2019
[0204] Hong, M., & Lee, V. M. (1997). Insulin and insulin-like growth factor- 1 regulate tau phosphorylation in cultured human neurons. The Journal of Biological Chemistry, 272(31), 19547-19553. https: / / doi.org / 10.1074 / jbc.272.31.19547
[0205] Hoyer, S. (2004). Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. European Journal of Pharmacology, 490(1-3), 115-125. https: / / doi.Org / 10.1016 / j.ejphar.2004.02.049
[0206] Hughes, T. M., & Craft, S. (2016). The role of insulin in the vascular contributions to age- related dementia. Biochimica et Biophysica Acta, 1862(5), 983-991. https: / / doi.Org / 10.1016 / j.bbadis.2015.l 1.013
[0207] Janson, J., Laedtke, T., Parisi, J. E , O’Brien, P , Petersen, R. C , & Butler, P. C. (2004). Increased risk of type 2 diabetes in Alzheimer disease. Diabetes, 53(2), 474-481. https: / / doi.Org / 10.2337 / diabetes.53.2.474
[0208] Jin, Y., Tu, Q., & Liu, M. (2018). MicroRNA 125b regulates Alzheimer’s disease through SphKl regulation. Molecular Medicine Reports, 18(2), 2373-2380. https: / / doi.org / 10.3892 / mmr.2018.9156
[0209] Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015a). Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 29(2), 589-596. https: / / doi.org / 10.1096 / fj.14-262048
[0210] Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015b). DysfunctionallyAtty. Dkt. No. 186563.00009phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 29(2), 589-596. https: / / doi.org / 10.1096 / fj.14-262048
[0211] Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015c). Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 29(2), 589-596. https: / / doi.org / 10.1096 / fj.14-262048
[0212] Kapogiannis, D., & Mattson, M. P. (2011). Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. The Lancet. Neurology, 10(2), 187-198. https: / / doi.org / 10.1016 / S1474-4422(10)70277-5
[0213] Kellar, D., & Craft, S. (2020). Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. The Lancet. Neurology, 19(9), 758-766. https : / / doi . org / 10.1016 / S 1474-4422(20)30231-3
[0214] Kellar, D., Lockhart, S. N., Aisen, P., Raman, R., Rissman, R. A., Brewer, J., & Craft, S. (2021). Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profdes in Mild Cognitive Impairment and Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease, 8(3), 240-248. https: / / doi.org / 10.14283 / jpad.2021.14
[0215] Kim, B., Figueroa-Romero, C., Pacut, C., Backus, C., & Feldman, E. L. (2015). Insulin Resistance Prevents AMPK-induced Tau Dephosphorylation through Akt-mediated Increase in AMPKSer-485 Phosphorylation. The Journal of Biological Chemistry, 290(31), 19146-19157. https: / / doi.org / 10.1074 / jbc.M115.636852
[0216] Kloosterman, W. P., Lagendijk, A. K., Ketting, R. F., Moulton, J. D., & Plasterk, R. H. A. (2007). Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biology, 5(8), e203. https: / / doi.org / 10.1371 / journal.pbio.0050203Atty. Dkt. No. 186563.00009
[0217] Kumar, A., Kim, S., Su, Y., Sharma, M., Kumar, P., Singh, S., Lee, J., Furdui, C. M., Singh, R., Hsu, F.-C., Kim, J., Whitlow, C. T., Nader, M. A., & Deep, G. (2021a). Brain cell- derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone. EBioMedicine, 63, 103192. https: / / doi.Org / 10.1016 / j.ebiom.2020.103192
[0218] Kumar, A., Kim, S., Su, Y., Sharma, M., Kumar, P., Singh, S., Lee, J., Furdui, C. M., Singh, R., Hsu, F.-C., Kim, J., Whitlow, C. T., Nader, M. A., & Deep, G. (2021b). Brain cell- derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone. EBioMedicine, 63, 103192. https: / / doi.Org / 10.1016 / j.ebiom.2020.103192
[0219] Kumar, A., Kim, S., Su, Y., Sharma, M., Kumar, P., Singh, S., Lee, J., Furdui, C. M., Singh, R., Hsu, F.-C., Kim, J., Whitlow, C. T., Nader, M. A., & Deep, G. (2021c). Brain cell- derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone. EBioMedicine, 63, 103192. https: / / doi.Org / 10.1016 / j.ebiom.2020.103192
[0220] Kumar, A., Nader, M. A., & Deep, G. (2024). Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust. Pharmacological Reviews, 76(2), 199-227. https: / / doi.Org / 10.l 124 / pharmrev.122.000788
[0221] Kumar, A., Sharma, M., Su, Y., Singh, S., Hsu, F.-C., Neth, B. J., Register, T. C., Blennow, K., Zetterberg, H., Craft, S., & Deep, G. (2022a). Small extracellular vesicles in plasma reveal molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment. Brain Communications, 4(6), fcac262. https: / / doi.org / 10.1093 / braincomms / fcac262
[0222] Kumar, A., Sharma, M„ Su, Y., Singh, S., Hsu, F.-C., Neth, B. J., Register, T. C., Blennow, K., Zetterberg, H., Craft, S., & Deep, G. (2022b). Small extracellular vesicles in plasma reveal molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment. Brain Communications, 4(6). https: / / doi.org / 10.1093 / braincomms / fcac262
[0223] Kumar, A., Sharma, M., Su, Y., Singh, S., Hsu, F.-C., Neth, B. J., Register, T. C., Blennow, K., Zetterberg, H., Craft, S., & Deep, G. (2022c). Small extracellular vesicles in plasma revealAtty. Dkt. No. 186563.00009molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment. Brain Communications, 4(6). https: / / doi.org / 10.1093 / braincomms / fcac262
[0224] Kumar, A., Su, Y., Sharma, M., Singh, S., Kim, S., Peavey, J. J., Suerken, C. K., Lockhart, S. N., Whitlow, C. T., Craft, S., Hughes, T. M., & Deep, G. (2023a). MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer’s disease. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 19(11), 4952-4966. https: / / doi.org / 10.1002 / alz.13055
[0225] Kumar, A., Su, Y., Sharma, M., Singh, S., Kim, S., Peavey, J. J., Suerken, C. K., Lockhart, S. N., Whitlow, C. T., Craft, S., Hughes, T. M., & Deep, G. (2023b). MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer’s disease. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 19(11), 4952-4966. https: / / doi.org / 10.1002 / alz.13055
[0226] Kumar, A., Su, Y., Sharma, M., Singh, S., Kim, S., Peavey, J. J., Suerken, C. K., Lockhart, S. N., Whitlow, C. T., Craft, S., Hughes, T. M., & Deep, G. (2023c). MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer’s disease. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 19(11), 4952-4966. https: / / doi.org / ! 0.1002 / alz.13055
[0227] Lin, H., Tas, E., Borsheim, E., & Mercer, K. E. (2020). Circulating miRNA Signatures Associated with Insulin Resistance in Adolescents with Obesity. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 13, 4929-4939. https: / / doi.org / 10.2147 / DMSO.S273908
[0228] Lugli, G., Cohen, A. M., Bennett, D. A., Shah, R. C., Fields, C. J., Hernandez, A. G., & Smalheiser, N. R. (2015). Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PloS One, 10(10), e0139233. https: / / doi.org / 10.1371 / journal.pone.0139233
[0229] Lukiw, W. J. (2007). Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. Neuroreport, 18(3), 297-300. https: / / doi.org / 10.1097 / WNR.0b013e3280148e8bAtty. Dkt. No. 186563.00009
[0230] Maimaiti, S., Frazier, H. N., Anderson, K. L., Ghoweri, A. O , Brewer, L. D., Porter, N. M., & Thibault, O. (2017). Novel calcium-related targets of insulin in hippocampal neurons. Neuroscience, 364, 130-142. https: / / doi.Org / 10.1016 / j.neuroscience.2017.09.019
[0231] Manning, B. D., & Toker, A. (2017). AKT / PKB Signaling: Navigating the Network. Cell, 169(3), 381-405. https: / / doi.Org / 10.1016 / j.cell.2017.04.001
[0232] Mansur, R. B , Delgado-Peraza, F., Subramaniapillai, M., Lee, Y., lacobucci, M., Nasri, F., Rodrigues, N., Rosenblat, J. D., Brietzke, E„ Cosgrove, V. E„ Kramer, N. E„ Suppes, T., Raison, C. L., Fagiolini, A., Rasgon, N., Chawla, S., Nogueras-Ortiz, C., Kapogiannis, D., & McIntyre, R. S. (2021a). Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. Journal of Psychiatric Research, 133, 82-92. https: / / doi.Org / 10.1016 / j.jpsychires.2020.12.007
[0233] Mansur, R. B., Delgado-Peraza, F., Subramaniapillai, M., Lee, Y., lacobucci, M., Nasri, F., Rodrigues, N., Rosenblat, J. D., Brietzke, E., Cosgrove, V. E., Kramer, N. E., Suppes, T., Raison, C. L., Fagiolini, A., Rasgon, N., Chawla, S., Nogueras-Ortiz, C., Kapogiannis, D., & McIntyre, R. S. (2021b). Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. Journal of Psychiatric Research, 133, 82-92. https: / / doi.org / ! 0.1016 / j .jpsychires.2020.12.007
[0234] Marks, J. L., Porte, D., Stahl, W. L., & Baskin, D. G. (1990). Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology, 127(6), 3234-3236. https: / / doi.org / 10.1210 / endo-127-6-3234
[0235] McKeever, P. M., Schneider, R., Taghdiri, F., Weichert, A., Multani, N., Brown, R. A., Boxer, A. L., Karydas, A., Miller, B., Robertson, J., & Tartaglia, M. C. (2018). MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer’s Disease. Molecular Neurobiology, 55(12), 8826-8841. https: / / doi.org / 10.1007 / sl2035-018-1032-x
[0236] Milstein, J. L., & Ferris, H. A. (2021). The brain as an insulin-sensitive metabolic organ. Molecular Metabolism, 52, 101234. https: / / doi.Org / 10.1016 / j.molmet.2021.101234Atty. Dkt. No. 186563.00009
[0237] Mishra, S., Kumar, A., Kim, S., Su, Y., Singh, S., Sharma, M., Almousa, S., Rather, H. A., Jain, H., Lee, J., Furdui, C. M., Ahmad, S., Ferrario, C. M., Punzi, H. A., Chuang, C.-C., Wabitsch, M., Kritchevsky, S. B., Register, T. C., & Deep, G. (2023a). A Liquid Biopsy-Based Approach to Isolate and Characterize Adipose Tissue-Derived Extracellular Vesicles from Blood. ACS Nano, 17(11), 10252-10268. https: / / doi.org / 10.1021 / acsnano.3c00422
[0238] Mishra, S., Kumar, A., Kim, S., Su, Y., Singh, S., Sharma, M., Almousa, S., Rather, H. A., Jain, H., Lee, J., Furdui, C. M., Ahmad, S., Ferrario, C. M., Punzi, H. A., Chuang, C.-C., Wabitsch, M., Kritchevsky, S. B., Register, T. C., & Deep, G. (2023b). A Liquid Biopsy-Based Approach to Isolate and Characterize Adipose Tissue-Derived Extracellular Vesicles from Blood. ACS Nano, 17(11), 10252-10268. https: / / doi.org / 10.1021 / acsnano.3c00422
[0239] Mishra, S., Kumar, A., Kim, S., Su, Y., Singh, S., Sharma, M., Almousa, S., Rather, H. A., Jain, H., Lee, J., Furdui, C. M., Ahmad, S., Ferrario, C. M., Punzi, H. A., Chuang, C.-C., Wabitsch, M., Kritchevsky, S. B., Register, T. C., & Deep, G. (2023c). A Liquid Biopsy-Based Approach to Isolate and Characterize Adipose Tissue-Derived Extracellular Vesicles from Blood. ACS Nano, 17(11), 10252-10268. https: / / doi.org / 10.1021 / acsnano.3c00422
[0240] Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017a). Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 9. https: / / doi.org / 10.3389 / fnagi.2017.00118
[0241] Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017b). Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 9, 118. https: / / doi.org / 10.3389 / fnagi.2017.00118
[0242] Mullins, R. J., Mustapic, M., Goetzl, E. J., & Kapogiannis, D. (2017a). Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease. Human Brain Mapping, 38(4), 1933-1940. https: / / doi.org / 10.1002 / hbm.23494
[0243] Mullins, R. J., Mustapic, M., Goetzl, E. J., & Kapogiannis, D. (2017b). Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease. Human Brain Mapping, 38(4), 1933-1940. https: / / doi.org / 10.1002 / hbm.23494Atty. Dkt. No. 186563.00009
[0244] Mustapic, M., Tran, J., Craft, S., & Kapogiannis, D. (2019a). Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer’s Disease. Journal of Alzheimer’s Disease : JAD, 69(2), 489-498. https: / / doi.org / 10.3233 / JAD-180578
[0245] Mustapic, M., Tran, J., Craft, S., & Kapogiannis, D. (2019b). Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer’s Disease. Journal of Alzheimer’s Disease : JAD, 69(2), 489-498. https: / / doi.org / 10.3233 / JAD-180578
[0246] Nasca, C., Dobbin, J., Bigio, B., Watson, K., de Angelis, P., Kautz, M., Cochran, A., Mathe, A. A., Kocsis, J. H., Lee, F. S., Murrough, J. W., McEwen, B. S., & Rasgon, N. (2021). Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. Molecular Psychiatry, 26(9), 5140- 5149. https: / / doi.org / 10.1038 / s41380-020-0804-7
[0247] Norman, M., Ter-Ovanesyan, D., Trieu, W., Lazarovits, R., Kowal, E. J. K., Lee, J. H., Chen-Plotkin, A. S., Regev, A., Church, G. M., & Walt, D. R. (2021a). L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nature Methods, 18(6), 631— 634. https: / / doi . org / 10.1038 / s41592-021-01174-8
[0248] Norman, M., Ter-Ovanesyan, D., Trieu, W , Lazarovits, R., Kowal, E. J. K., Lee, J. H., Chen-Plotkin, A. S., Regev, A., Church, G. M., & Walt, D. R. (2021b). L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nature Methods, 18(6), 631— 634. https: / / doi . org / 10.1038 / s41592-021-01174-8
[0249] Perluigi, M., Picca, A., Montanari, E., Calvani, R., Marini, F., Matassa, R., Tramutola, A., Villani, A., Familiari, G., Domenico, F. Di, Butterfield, D. A., Oh, K. J., Marzetti, E., Valentini, D., & Barone, E. (2022). Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 18(8), 1498-1510. https: / / doi.org / 10.1002 / alz.12499
[0250] Plaisance, V., Abderrahmani, A., Perret-Menoud, V., Jacquemin, P., Lemaigre, F., & Regazzi, R. (2006). MicroRNA-9 controls the expression of Granuphilin / Slp4 and the secretoryAtty. Dkt. No. 186563.00009response of insulin-producing cells. The Journal of Biological Chemistry, 281(37), 26932-26942. https: / / doi.org / 10.1074 / jbc.M601225200
[0251] Pulliam, L., Sun, B., Mustapic, M., Chawla, S., & Kapogiannis, D. (2019). Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer’ s disease. Journal of Neurovirology, 25(5), 702-709. https: / / doi.org / 10.1007 / sl3365-018-0695-4
[0252] Ramanjaneya, M., Bettahi, I., Pawar, K., Halabi, N. M., Moin, A. S. M., Sathyapalan, T., Abou-Samra, A. B., Atkin, S. L., & Butler, A. E. (2022). MicroRNA Changes Up to 24 h following Induced Hypoglycemia in Type 2 Diabetes. International Journal of Molecular Sciences, 23(23). https: / / doi.org / 10.3390 / ijms232314696
[0253] Rhea, E. M., Banks, W. A., & Raber, J. (2022). Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites. Biomedicines, 10(7). https : / / doi . org / 10.3390 / biomedicines 10071582
[0254] Ribeiro, I. M. R., & Antunes, V. R. (2018). The role of insulin at brain-liver axis in the control of glucose production. American Journal of Physiology. Gastrointestinal and Liver Physiology, 315(4), G538-G543. https: / / doi.org / 10.1152 / ajpgi.00290.2017
[0255] Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005). Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. Journal of Alzheimer’s Disease : JAD, 8(3), 247-268. https: / / doi.org / 10.3233 / jad-2005-8304
[0256] Rosenbloom, M., Barclay, T. R., Kashyap, B., Hage, L., O’Keefe, L. R., Svitak, A., Pyle, M., Frey, W., & Hanson, L. R. (2021). A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer’s Disease. Drugs & Aging, 38(5), 407-415. https: / / doi.org / 10.1007 / s40266-021-00845-7
[0257] Samatov, T. R., Wicklein, D., & Tonevitsky, A. G. (2016). LI CAM: Cell adhesion and more. Progress in Histochemistry and Cytochemistry, 51(2), 25-32. https: / / doi.Org / 10.1016 / j.proghi.2016.05.001Atty. Dkt. No. 186563.00009
[0258] Sanguinetti, E., Guzzardi, M. A., Panetta, D., Tripodi, M., De Sena, V., Quaglierini, M., Burchielli, S., Salvadori, P. A., & lozzo, P. (2019). Combined Effect of Fatty Diet and Cognitive Decline on Brain Metabolism, Food Intake, Body Weight, and Counteraction by Intranasal Insulin Therapy in 3*Tg Mice. Frontiers in Cellular Neuroscience, 13, 188. https: / / doi.org / 10.3389 / fncel.2019.00188
[0259] Santiago, J. A., & Potashkin, J. A. (2021). The Impact of Disease Comorbidities in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 13, 631770. https : / / doi . org / 10.3389 / fnagi .2021.631770
[0260] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chetelat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021). Alzheimer’s disease. Lancet (London, England), 397(10284), 1577-1590. https: / / doi.org / 10.1016 / S0140-6736(20)32205-4
[0261] Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Kustermann, E., Arndt, S., Jacobs, A. H., Krone, W., Kahn, C. R., & Bruning, J. C. (2004). Role for neuronal insulin resistance in neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America, 101(9), 3100-3105. https: / / doi.org / 10.1073 / pnas.0308724101
[0262] S^dzikowska, A., & Szablewski, L. (2021). Insulin and Insulin Resistance in Alzheimer’s Disease. International Journal of Molecular Sciences, 22(18). https: / / doi.org / 10.3390 / ijms22189987
[0263] Singh, D., Dobrowolny, H., Kapogiannis, D., & Steiner, J. (2023). Canonical insulin signaling is not significantly impaired in early stages of depression. European Archives of Psychiatry and Clinical Neuroscience, 273(1), 283-286. https: / / doi.org / 10.1007 / s00406-022- 01412-w
[0264] Sliwowska, J. H., Fergani, C., Gawalek, M., Skowronska, B., Fichna, P., & Lehman, M. N. (2014). Insulin: its role in the central control of reproduction. Physiology & Behavior, 133, 197-206. https: / / doi.Org / 10.1016 / j.physbeh.2014.05.021Atty. Dkt. No. 186563.00009
[0265] Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L , Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005a). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? Journal of Alzheimer’s Disease : JAD, 7(1), 63-80. https: / / doi.org / 10.3233 / jad-2005-7107
[0266] Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005b). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease— is this type 3 diabetes? Journal of Alzheimer’s Disease : JAD, 7(1), 63-80. https: / / doi.org / 10.3233 / jad-2005-7107
[0267] Stouffer, M. A., Woods, C. A., Patel, J. C., Lee, C. R., Witkovsky, P., Bao, L., Machold, R. P., Jones, K. T., de Vaca, S. C., Reith, M. E. A., Carr, K. D , & Rice, M. E. (2015). Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nature Communications, 6, 8543. https: / / doi.org / 10.1038 / ncomms9543
[0268] Strachan, M. W. J. (2011). R D Lawrence Lecture 2010. The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabetic Medicine : A Journal of the British Diabetic Association, 28(2), 141-147. https: / / doi.org / 10.1111 / j .1464- 5491.2010.03199.x
[0269] Sugawa, M., Ono, K., Yasui, Y., Kishi, T., & Tsumori, T. (1997a). Enhancement of neurite outgrowth by the soluble form of human LI (neural cell adhesion molecule). Neuroreport, 8(14), 3157-3162. https: / / doi .org / 10.1097 / 00001756- 199709290-00030
[0270] Sugawa, M„ Ono, K., Yasui, Y., Kishi, T., & Tsumori, T. (1997b). Enhancement of neurite outgrowth by the soluble form of human LI (neural cell adhesion molecule). Neuroreport, 8(14), 3157-3162. https: / / doi.org / 10.1097 / 00001756-199709290-00030
[0271] Sun, Y., Yu, Z., Zhang, Y., Wang, H., Chi, Z., Chen, X., & Xu, D. (2022). Downregulation of microRNA-342-3p Eases Insulin Resistance and Liver Gluconeogenesis via Regulating Rfx3 in Gestational Diabetes Mellitus. Critical Reviews in Eukaryotic Gene Expression, 32(6), 83-95. https: / / doi.org / 10.1615 / CritRevEukaryotGeneExpr.2022043275Atty. Dkt. No. 186563.00009
[0272] Swaminathan, S. K., Ahlschwede, K. M., Sarma, V., Curran, G. L., Omtri, R. S., Decklever, T., Lowe, V. J., Poduslo, J. F., & Kandimalla, K. K. (2018). Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 38(5), 904-918. https: / / doi.org / 10.1177 / 0271678X17709709
[0273] Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., & Arnold, S. E. (2012a). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of Clinical Investigation, 122(4), 1316-1338. https: / / doi.org / 10.1172 / JCI59903
[0274] Talbot, K„ Wang, H.-Y., Kazi, H, Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., & Arnold, S. E. (2012b). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of Clinical Investigation, 122(4), 1316-1338. https : / / doi . org / 10.1172 / JCI59903
[0275] Tan, L., Yu, J.-T., Liu, Q.-Y., Tan, M.-S., Zhang, W., Hu, N., Wang, Y.-L., Sun, L., Jiang, T., & Tan, L. (2014). Circulating miR-125b as a biomarker of Alzheimer’s disease. Journal of the Neurological Sciences, 336(1-2), 52-56. https: / / doi.Org / 10.1016 / j.jns.2013.10.002
[0276] Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006). Critical nodes in signalling pathways: insights into insulin action. Nature Reviews Molecular Cell Biology, 7(2), 85-96. https: / / doi.org / 10.1038 / nrml837
[0277] Tramutola, A., Lanzillotta, C., Di Domenico, F., Head, E., Butterfield, D. A., Perluigi, M., & Barone, E. (2020). Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiology of Disease, 137, 104772. https: / / doi.Org / 10.1016 / j.nbd.2020.104772Atty. Dkt. No. 186563.00009
[0278] Uemura, E., & Greenlee, H. W. (2006). Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3. Experimental Neurology, 198(1), 48-53. https : / / doi . org / 10.1016 / j . expneurol .2005.10.035
[0279] Valle-Tamayo, N., Perez-Gonzalez, R., Chiva-Blanch, G., Belbin, O., Serrano-Requena, S., Sirisi, S., Cervantes Gonzalez, A., Giro, O., Sanchez-Aced, E., Dols-Icardo, O., Alcolea, D., Carmona-Iragui, M., Jimenez, A., Lleo, A., Fortea, J., & lulita, M. F. (2022). Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Journal of Visualized Experiments : JoVE, 186. https: / / doi.org / 10.3791 / 64107
[0280] van der Heide, L. P., Kamal, A., Artola, A., Gispen, W. H., & Ramakers, G. M. J. (2005). Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. Journal of Neurochemistry, 94(4), 1158-1166. https: / / doi.org / 10.! 111 / j.1471-4159.2005.03269.x
[0281] Vandal, M., White, P. J., Tremblay, C , St-Amour, I., Chevrier, G., Emond, V., Lefranqois, D., Virgili, J., Planel, E., Giguere, Y., Marette, A., & Calon, F. (2014). Insulin reverses the high- fat diet-induced increase in brain Ap and improves memory in an animal model of Alzheimer disease. Diabetes, 63(12), 4291-4301. https: / / doi.org / 10.2337 / dbl4-0375
[0282] Vella, L. J., Scicluna, B. J., Cheng, L., Bawden, E. G., Masters, C. L., Ang, C.-S., Willamson, N., McLean, C., Barnham, K. J., & Hill, A. F. (2017a). A rigorous method to enrich for exosomes from brain tissue. Journal of Extracellular Vesicles, 6(1), 1348885. https: / / doi.org / 10.1080 / 20013078.2017.1348885
[0283] Vella, L. J., Scicluna, B. J., Cheng, L., Bawden, E. G., Masters, C. L., Ang, C.-S., Willamson, N., McLean, C., Bamham, K. J., & Hill, A. F. (2017b). A rigorous method to enrich for exosomes from brain tissue. Journal of Extracellular Vesicles, 6(1), 1348885. https: / / doi.org / 10.1080 / 20013078.2017.1348885
[0284] Visconte, C., Golia, M. T., Fenoglio, C., Serpente, M., Gabrielli, M., Arcaro, M., Sorrentino, F., Busnelli, M., Arighi, A., Fumagalli, G., Rotondo, E., Rossi, P., Arosio, B., Scarpini, E., Verderio, C., & Galimberti, D. (2023). Plasma microglial-derived extracellular vesicles areAtty. Dkt. No. 186563.00009increased in frail patients with Mild Cognitive Impairment and exert a neurotoxic effect. GeroScience, 45(3), 1557-1571. https: / / doi.org / 10.1007 / sll357-023-00746-0
[0285] Walker, K. A., Chawla, S., Nogueras-Ortiz, C., Coresh, J., Sharrett, A. R., Wong, D. F., Jack, C. R, Spychalla, A. J., Gottesman, R. F., & Kapogiannis, D. (2021). Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study. Neurobiology of Aging, 97, 65-72. https: / / doi.Org / 10.1016 / j.neurobiolaging.2020.09.022
[0286] Woodworth, D. C., Sheikh-Bahaei, N., Scambray, K. A., Phelan, M. J., Perez-Rosendahl, M., Corrada, M. M., Kawas, C. H., Sajjadi, S. A., & Alzheimer’s Disease Neuroimaging Initiative. (2022). Dementia is associated with medial temporal atrophy even after accounting for neuropathologies. Brain Communications, 4(2), fcac052. https: / / doi.org / 10.1093 / braincomms / fcac052
[0287] Yarchoan, M., Toledo, J. B., Lee, E. B , Arvanitakis, Z , Kazi, H., Han, L.-Y., Louneva, N., Lee, V. M.-Y., Kim, S. F., Trojanowski, J. Q., & Arnold, S. E. (2014). Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathologica, 128(5), 679-689. https : / / doi . org / 10.1007 / s00401-014-1328-5
[0288] You, Y., & Ikezu, T. (2019). Emerging roles of extracellular vesicles in neurodegenerative disorders. Neurobiology of Disease, 130, 104512. https: / / doi.Org / 10.1016 / j.nbd.2019.104512
[0289] You, Y., Muraoka, S., Jedrychowski, M. P., Hu, J., McQuade, A. K., Young-Pearse, T., Aslebagh, R., Shaffer, S. A., Gygi, S. P., Blurton-Jones, M., Poon, W. W., & Ikezu, T. (2022a). Human neural cell type-specific extracellular vesicle proteome defines disease-related molecules associated with activated astrocytes in Alzheimer’s disease brain. Journal of Extracellular Vesicles, 11(1), el2183. https: / / doi.org / 10.1002 / jev2.12183
[0290] You, Y., Muraoka, S., Jedrychowski, M. P., Hu, J., McQuade, A. K., Young-Pearse, T., Aslebagh, R., Shaffer, S. A., Gygi, S. P., Blurton-Jones, M., Poon, W. W., & Ikezu, T. (2022b). Human neural cell type-specific extracellular vesicle proteome defines disease-related moleculesAtty. Dkt. No. 186563.00009associated with activated astrocytes in Alzheimer’s disease brain. Journal of Extracellular Vesicles, 11(1), el2183. https: / / doi.org / 10.1002 / jev2.12183
[0291] You, Y., Zhang, Z., Sultana, N., Ericsson, M., Martens, Y. A., Sun, M., Kanekiyo, T., Ikezu, S., Shaffer, S. A., & Ikezu, T. (2023). ATP1A3 as a target for isolating neuron-specific extracellular vesicles from human brain and biofluids. Science Advances, 9(37), eadi3647. https: / / doi.org / 10.! 126 / sciadv.adi3647
[0292] Zhang, D., Yamaguchi, S., Zhang, X., Yang, B., Kurooka, N., Sugawara, R., Albuayjan, H. El. H., Nakatsuka, A., Eguchi, J., Hiyama, T. Y., Kamiya, A., & Wada, J. (2021). Upregulation of Mir342 in Diet-Induced Obesity Mouse and the Hypothalamic Appetite Control. Frontiers in Endocrinology, 12, 727915. https: / / doi.org / 10.3389 / fendo.2021.727915
[0293] Zhao, W„ Chen, H„ Xu, H„ Moore, E„ Meiri, N„ Quon, M. J., & Alkon, D. L. (1999). Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. The Journal of Biological Chemistry, 274(49), 34893-34902. https: / / doi.org / 10.1074 / jbc.274.49.34893
[0294] Zhao, W.-Q., De Felice, F G., Fernandez, S., Chen, H., Lambert, M P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008). Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 22(1), 246-260. https: / / doi.org / 10.1096 / lj.06-7703com
[0295] Zhao, W.-Q., & Townsend, M. (2009). Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease. Biochimica et Biophysica Acta, 1792(5), 482-496. https: / / doi.Org / 10.1016 / j.bbadis.2008.10.014
[0296]
[0297] In the foregoing description, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is notAtty. Dkt. No. 186563.00009specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and / or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
[0298] Citations to a number of patent and non-patent references may be made herein. The cited references are incorporated by reference herein in their entireties. In the event that there is an inconsistency between a definition of a term in the specification as compared to a definition of the term in a cited reference, the term should be interpreted based on the definition in the specification.
Claims
Atty. Dkt. No. 186563.00009CLAIMS1. A method of enriching neuron-derived small extracellular vesicles (NDEs) from a plurality of small extracellular vesicles (sEVs), the method comprising contacting the plurality of small extracellular vesicles (sEVs) with at least one binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate binding reagent-NDE complexes, wherein the at least one NDE-specific marker is selected from synaptosome associated protein 25 (SNAP-25), glycoprotein M6A(GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GABRA1), or any combination thereof.
2. The method of claim 1, wherein the method further comprises contacting the binding reagent-NDE complexes with a capture reagent to generate capture reagent-binding reagent-NDE complexes, wherein the capture reagent binds to the at least one binding reagent.
3. The method of claim 2, wherein the method further comprises washing the capture reagentbinding reagent-NDE complexes and / or eluting the enriched NDEs from the capture reagentbinding reagent-NDE complexes.
4. The method of claim 1, wherein the plurality of sEVs are isolated from a sample from a subject by centrifuging the sample, filtering the centrifuged sample, treating the filtered sample with at least one of DNase, RNase, or proteinase, and separating the treated sample using a molecular weight cut-off column, wherein the plurality of sEVs are isolated in the retentate of the molecular weight cut-off column.
5. The method of claim 4, wherein centrifuging comprises centrifuging the sample at about 2000xg for about 1 to about 20 min.
6. The method of claim 4, wherein filtering the centrifuged sample comprises filtering the centrifuged sample through a 0.22 pm filter.
7. The method of claim 4, wherein the molecular weight cut-off column has a cut-off of greater than about 100 kDa, greater than about 150 kDa, greater than about 200 kDa, greater than about 250 kDa, greater than about 300 kDa, greater than about 350 kDa, greater than about 400 kDa, greater than about 500 kDa, optionally, wherein the cut-off is about 300 kDa.Atty. Dkt. No. 186563.000098. A method comprising:centrifuging a sample comprising small extracellular vesicles (sEVs);filtering the centrifuged sample;treating the filtered sample with at least one of DNase, RNase, or proteinase;separating the treated sample using a molecular weight cut-off column, wherein the plurality of sEVs are isolated in the retentate of the molecular weight column to isolate a plurality of small extracellular vesicles (sEVs);contacting the plurality of sEVs with at least one binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate binding reagent-NDE complexes, wherein the NDE-specific marker is selected from synaptosome associated protein 25 (SNAP -25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alphal (GAB RAI), or a combination thereof; andcontacting the binding reagent-NDE complexes with a capture reagent to generate capture reagentbinding reagent-NDE complexes, wherein the capture reagent binds to the at least one binding reagent.
9. The method of claim 4, wherein centrifuging comprises centrifuging the sample at about 2000xg for about 1 to about 20 min.
10. The method of claim 8, wherein filtering the centrifuged sample comprises filtering the centrifuged sample through a 0.22 pm filter.
11. The method of claim 8, wherein the molecular weight cut-off column has a cut-off of greater than about 100 kDa, greater than about 150 kDa, greater than about 200 kDa, greater than about 250 kDa, greater than about 300 kDa, greater than about 350 kDa, greater than about 400 kDa, greater than about 500 kDa, optionally, wherein the cut-off is about 300 kDa.Atty. Dkt. No. 186563.0000912. The method of claim 8, wherein the method further comprises washing the capture reagentbinding reagent-NDE complexes and / or eluting the enriched NDEs from the capture reagentbinding reagent-NDE complexes.
13. The method of any one of the preceding claims, wherein the at least one NDE-specific marker comprises SNAP-25.
14. The method of any one of the preceding claims, wherein the at least one binding reagent is an antibody or an antigen-binding fragment thereof.
15. The method of claim 14, wherein the antibody is a monoclonal antibody.
16. The method of claim 2 or 8, wherein the capture reagent is linked to a solid substrate.
17. The method of claim 16, wherein the solid substrate comprises beads, optionally, wherein the beads are agarose beads or magnetic beads.
18. The method of any one of the preceding claims, wherein(i) the at least one binding reagent comprises biotin and the capture reagent comprises streptavidin;(ii) the at least one binding reagent comprises glutathione and the capture reagent comprises glutathione S-transferase;(iii) the at least one binding reagent comprises maltose and the capture reagent comprises maltose binding protein;(iv) the at least one binding reagent comprises chitin and the capture reagent comprises chitin binding protein; or(v) the at least one binding reagent comprises fluorescein isothiocyanate (FITC) and the capture reagent comprises a FITC-specific antibody.
19. The method of claim 18, wherein the at least one binding reagent comprises biotin and the capture reagent comprises streptavidin.Atty. Dkt. No. 186563.0000920. The method of any one of claims 4-19, wherein the sample comprises blood or plasma.
21. The method of any one of the preceding claims, wherein the method further comprises detecting at least one marker in the NDEs.
22. The method of claim 21, wherein detecting comprises enzyme linked immunosorbent assay (ELISA).
23. The method of claim 22, wherein the ELISA comprises a nucleic acid linked immunosandwich assay.
24. The method of claim 21, wherein the at least one marker comprises MiR-342-3p, phosphoglycerate kinase 1 (PGK1), GDP dissociation inhibitor 1 (GDI1), interleukin 15 (IL-15), placental growth factor (PGF), PDZ And LIM Domain 5 (PDLIM5), SLP adaptor and CSK interacting membrane protein (SCIMP), citron Rho-interacting serine / threonine kinase (CIT), collagen type VI alpha 2 chain (COL6A2), Histone-lysine N-methyltransferase 2A (KMT2A), NOTCH3, Family With Sequence Similarity 78 Member A (FAM78A), Stromal Antigen 2 (STAG2), Multiple Epidermal Growth Factor-like Domains 8 (MEGF8), Scaffold Attachment Factor B (SAFB), Ubiquitin Specific Peptidase 34 (USP34), Adhesion G Protein-Coupled Receptor G1 (ADGRG1), Lemur Tyrosine Kinase-2 (LMTK2), RNA Exonuclease 1 Homolog (REX01), DENN Domain Containing 4B (DENND4B), Polyadenylate-binding protein 2 (PABPN1), Mitogen-Activated Protein Kinase 1 (MAPK1), Zinc Finger CCHC-Type Containing 7 (ZCCHC7), tao kinase 1 (TAOK1), triosephosphate isomerase 1 (TPI1), Myeloid / Lymphoid Or Mixed-Lineage Leukemia, Translocated To, 6 (MLLT6), or a combination thereof.
25. A kit or system comprising at least one binding reagent, wherein the at least one binding reagent is specific for one of synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), or gamma-aminobutyric acid type A receptor subunit alphal (GABRA1) and a capture reagent specific for the at least one binding reagent.
26. The kit or system of claim 25, wherein the kit comprises at least two binding reagents.
27. The kit or system of claim 25 or 26, whereinAtty. Dkt. No. 186563.00009(i) the at least one binding reagent comprises biotin and the capture reagent comprises streptavidin;(ii) the at least one binding reagent comprises glutathione and the capture reagent comprises glutathione S-transferase;(iii) the at least one binding reagent comprises maltose and the capture reagent comprises maltose binding protein;(iv) the at least one binding reagent comprises chitin and the capture reagent comprises chitin binding protein; or(v) the at least one binding reagent comprises fluorescein isothiocyanate (FITC) and the capture reagent comprises a FITC-specific antibody.
28. The kit or system of claim 25, wherein the kit or system further comprises at least one of:(a) a cell filter;(b) DNase;(c) RNase;(d) proteinase; or(e) a molecular weight cut-off column.
29. The kit or system of claim 25, wherein the kit or system further comprises instructions for performing the methods of any one of claims 1-24 using the kit or system.
30. The kit of claim 25, wherein the kit consists of a defined ready to use mixture of antibody-biotin-streptavidin-beads, optionally, wherein the beads are agarose or magnetic beads.
